Document Type  Study Protocol 
Document Date  December  20, 2018 
Official Title  Efficacy and Safety of gadoPI[INVESTIGATOR_555330] 
(CNS) Magnetic REsonance Imaging (MRI) 
Phase III Clinical Trial  
The PI[INVESTIGATOR_555331]  [STUDY_ID_REMOVED] 
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 2 / 79 
 
 
PROTOCOL  SYNOPSIS  
Trial  Title: Efficacy and Safety of gadopi[INVESTIGATOR_555332] (CNS)  Magnetic 
Resonance Imaging (MRI)   
Phase III Clinical Trial  
Trial  Product(s):  G03277 Active Ingredient(s):  gadopi[INVESTIGATOR_555333].:  2018 -003988 -54 IND No.:  123673  
Potential Participating countries (Potential Number of sites):  
Worldwide trial involving approximately 40 site s. 
Trial  Objectives  
As the trial is a multi -regional one, trial objectives are presented to meet with the respective 
regulatory authoritiesâ€™ submission purpose.  
Primary objective  1:  
o To demonstrate the superiority  of gadopi[INVESTIGATOR_555334]- enhanced MRI at 0.05 mmol/kg  body 
weight (BW) compared to unenhanced MRI for patien t referred for contrast- enhanced MRI 
of CNS, in terms of 3 lesion visualization  co-primary criteria ( border delineation, internal 
morphology and degree of contrast enhancement) using the patient as his/her own control. 
Primary objective  2: 
o To demonstrate the non- inferiority of gadopi[INVESTIGATOR_555335] 0.05 mmol/kg compared to 
gadobutrol at 0.1 mmol/kg in terms of 3 lesion visualization co-primary criteria (border 
delineation, internal morphology, degree of contrast enhancement ) for patient referred fo r 
contrast- enhanced MRI of CNS .  
For FDA , the primary objective 1 is to be achieved. The primary objective 2 will serve as one of the 
secondary objectives.  
For EMA, both primary objectives 1 and 2 are to be achieved. 
Secondary objectives: 
o To demonstrate the non- inferiority of gadopi[INVESTIGATOR_555336]  3 
lesion visualization co -primary criteria (border delineation, internal morphology, degree of 
contrast enhancement) for patient referred for contrast- enhanced MRI of CNS  (for FDA 
only). 
o To assess the following parameters with gadopi[INVESTIGATOR_555337]  
ïƒ¼ lesion visualization assessment by [CONTACT_1697]  
ïƒ¼ Improvement in lesion visualization scores  at patient -level  
ïƒ¼ Technical adequacy of images 
ïƒ¼ Number, size and location of lesions  
ïƒ¼ Diagnostic confidence 
ïƒ¼ Impact  of contrast-enhanced MRI on patient treatment plan  
ïƒ¼ Contrast to Noise Ratio (CNR)  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 3 / 79 
 
 
ïƒ¼ Percentage enhancement (E%) of lesion(s)  
ïƒ¼ Lesion to Background Ratio (LBR)  
ïƒ¼ Overall diagnostic preference  
o To assess the safety profile of gadopi[INVESTIGATOR_555338] s a prospective, multi- center, randomized, double -blind, controlled and cross -over 
design . 
The Investigational Medicinal Products (IMPs) used during the trial are gadopi[INVESTIGATOR_555339]. 
The p rimary criteria  1 will compare gadopi[INVESTIGATOR_555334] -enhanced MRI (pre + post images = paired 
images) to unenhanced MRI (pre images), using the patient as h is/her own control.  
The primary criteria  2 will compare gadopi[INVESTIGATOR_555334] -enhanced MRI (paired images) to gadobutrol -
enhanced MRI (paired images).  
Patients, once informed consent form (ICF) signed, will perform a screening visit (V1) to confirm 
trial eligibility, then will be randomized in the trial to determ ine the order of IMP injection. Each of 
the 2 MRI visits  (V2 and V4)  will be followed by a safety visit (V3 and V5) performed 1 day after 
the MRI visit.  
Two MRIs will be obtained for each patient: gadopi[INVESTIGATOR_555334]- enhanced MRI and gadobutrol -enhanced 
MRI (see Figure 1) , however the nature of the contrast agent s injected at V isit 2 and at Visit 4 will 
be randomly assigned by [CONTACT_53177] ( IWRS ). 
The investigator and the patient will remain blinded to IMPs allocation (nature of the IMPs and 
order of the IMP injection). A designated unblinded site staff member will be in charge of 
preparation and administration of the IMPs. 
The randomization scheme will allocate patient s in a 1:[ADDRESS_729060] experienced in 
MRI of CNS  will be appointed at the start of the trial to read all images of  patients included at the 
site (on-site read) . 
In addition, images will be evaluated by [CONTACT_555421] a 
centralized manner. All images will be sent to a core  laboratory, which  will prepare the images for 
evaluation. 
The blinded image evaluations (off-site read) will be performed by 3 independent blinded 
radiologists for the reading of random images and by 3 additional independent blinded radiologists 
for the g lobal pairs assessment . An imaging electronic Case Report Form (eCRF ) will be used to 
ensure that the images are properly aligned and to ensure that all necessary data for the trial purpose 
are documented by [CONTACT_555422].  
To allow exact matching of lesions between imaging modalities (Pre  and Paired), between the two 
MR examinations with gadopi[INVESTIGATOR_555337], and among [ADDRESS_729061] (lesion tracker) will perform lesion tracking, separate from the image evaluation by [CONTACT_555423]. 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 4 / [ADDRESS_729062] patient â€™s 
visits . 
During the trial, the safety will be monitored and assessed based on the reporting of adverse events 
(AEs) , the results of vital signs  measurement , the injection site tolerance  evaluation  and the clinical 
laboratory parameters (blood  samples).  
Number of patients : 250  
Eligibility criteria  
Inclusion criteria: 
1. Female or male adult patient (patient having reached legal majority age).  
2. Patient presenting  with known or highly suspected CNS lesion(s) with focal areas of 
disrupted Blood Brain Barrier  (BBB) (e.g., primary and secondary tumors ) based on 
results of a previous imaging procedure such as Computed Tomography (CT) or MRI, 
which should have been performed within [ADDRESS_729063] -enhanced MRI examination for the purpose of 
the trial.  
4. If the patient was treated (either with radiation, surgery, biopsy or other re levant 
treatments) between previous imaging evaluation and trial MRI, there should still be a 
high suspi[INVESTIGATOR_555340](s) on the basis of available clinical information.  
5. Patient able and willing to participate in the trial. 
6. Patient having read the information and having provided his/her consent to participate 
in writing by [CONTACT_555424]. 
7. Patient affiliated to national health insurance according to local regulatory 
requirements.  
To be included in the trial, the patient must meet all the inclusion criteria.  
 
Non-inclusion criteria : 
1. Patient presenting extra cranial lesions and/or extra -dural lesions.  
2. Patient presenting with  an acute relapse of multiple sclerosis as qualifying CNS lesion. 
3. Patient presenting with known class III/IV congestive heart failure according to the 
[LOCATION_001] Heart Association classification (NYHA).  
4. Patient having received any investigational medicinal product within [ADDRESS_729064] agent (MRI or CT) with in [ADDRESS_729065] administration. 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 5 / 79 
 
 
8. Patient expected/scheduled to have any treatment or medical p rocedure (e.g. 
chemotherapy, radiotherapy, biopsy or surgery etcâ€¦) that may impact the aspects of the 
imaged lesions between the 2 MRI examinations. (Patients under corticosteroids and/ or 
maintenance chemotherapy with a stable dose at the time of screening  visit and 
throughout the trial can be included).  
9. Patient with anticipated, current or past condition (medical, psychological, social or 
geographical) that would compromise the patientâ€™s safety or her/his ability to 
participate in the trial.  
10. Patient unlik ely to comply with the protocol, e.g. uncooperative attitude, inability to 
return for follow -up visits and/or unlikelihood of completing the trial. 
11. Patient related to the investigator or any other trial staff or relative directly involved in 
the trial cond uct.  
Non-inclusion criteria to be checked at V1, V2 and V4: 
12. Patient presenting with acute or chronic renal insufficiency, defined as an estimated 
Glomerular Filtration Rate (eGFR) < 30 mL/min/1.[ADDRESS_729066] -feeding female patient (a female patient of childbearing potential or 
with amenorrhea for less than [ADDRESS_729067] trial visit).  
14. Patient with known contra- indication(s) to the use or with known sensitivity to one of 
the products under investigation or to other GBCAs (such as hypersensitivity, Post 
contrast acute kidney injury).  
Patient s presenting with one or more of the non-inclusion criteria must not be included in the trial. 
The diagnosis obtained from previous (qualifying) imaging examinations will be considered as 
medical history to assess inclusion criteria. All the trial efficacy  analys es will be only based on the 
images obtained through the trial MRI. 
Investigational Medicinal Product(s) administration  
Investigational Medicinal  Product (IMP) 1 : 
â€¢ gadopi[INVESTIGATOR_555334], single intravenous (IV) bolus injection at 0.05 mmol/kg BW 
Investigational Medicinal  Product (IMP) 2 : 
â€¢ gadobutrol, single intravenous (IV) bolus injection at 0.1 mmol/kg BW 
For both products, the recommended injection rate is 2 mL/second followed by a saline flush via 
manual injection or power injector. 
Trial duration for patients : 
Minimum trial duration for patient s: 4 days (if V1 and V2 done on the same day ) and the second 
MRI is done [ADDRESS_729068] one. 
Maximum trial duration for patient s: [ADDRESS_729069] one.  The trial includes a maximum of 5 visits: 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 6 / 79 
 
 
- One screening visit (V1) up to 7 days prior to inclusion ( V1 could be done on the same day 
as the randomization visit  (V2) if all the inclusion/non-inclusion criteria are met).  
- Two sequential imaging visits (V2 and V4, minimum interval 2 days and up to 14 days): 
each visit will consist of gadopi[INVESTIGATOR_555341] .  
- Two safety visits (V3 and V5): [ADDRESS_729070] been reviewed by [CONTACT_555425]. The patientâ€™s participation is defined as the period from the screening visit (ICF sig nature) to the last trial visit.  
Evaluation criteria  
Primary criteria 1 : 
o Lesion visualization (based on 3 co- primary criteria: border delineation, internal 
morphology and degree of contrast enhancement) will be assessed by 3 independent off -site 
blinded r eaders on Paired (pre+post) images versus Pre images for gadopi[INVESTIGATOR_555342] a 4-
point scale (off-site read)  
Primary criteria 2  (for EMA, secondary criteria for FDA) : 
o Lesion visualization (based on 3 co- primary criteria: border delineation, internal 
morphology and degree of contrast enhancement) will be assessed by 3 independent off -site 
blinded readers on Paired (pre+post) images for gadopi[INVESTIGATOR_555343] a 4 -point scale (off -site read).  
The evaluation for  the primary criteria will be performed f or up to the [ADDRESS_729071] enhancing lesions should be 
prioritized.  
The 3 co-primary criteria  (border delineation, internal morphology and degree of contrast 
enhancement) will be assessed  and the mean  of scores for each of the 3 co-primary criteria will be 
calculated as follows:  
Mean  of scores = score of the lesion 1 + score of the lesion 2 (if a ny) + score of the lesion 3 (if 
any)) divided by [CONTACT_555426] (up to [ADDRESS_729072] representative lesions).  
 
For each reader, only matching lesion between Paired images and Pre images will be considered for 
the purpose of the primary criteria [ADDRESS_729073], if the MR images are not assessable or if no matching lesion between 
Paired images of gadopi[INVESTIGATOR_555344], then the patient will not be included in 
the primary criteria 2 evaluation.  
 The mean of scores for each of the lesion visualization co - primary criteria and for each reader will 
range from 1 to 4. 
 
Secondary criteria :  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 7 / 79 
 
 
The following parameters will be evaluated  with gadopi[INVESTIGATOR_555337] :  
o Same as primary criteria 2, lesion visualization (based on 3 co- primary criteria: border 
delineation, internal morphology and degree of contrast enhancement) for gadopi[INVESTIGATOR_555345] (off-site read)  (For FDA only) . 
o Improvement in lesion visualization scores  at patie nt-level : a comparison of paired images 
to pre images with respect to the proportion of patients who have paired image scores that 
are greater ( â€œbetterâ€) , or same/worse ( â€œnot betterâ€ ) than the pre images. 
o Lesion visualization (based on 3 co- primary criteria: border delineation, internal 
morphology and degree of contrast enhancement) (on -site read)   
o Technical adequacy of images (on- site and off -site read)  
Images will be evaluated as technically adequate for diagnosis and assessable or not . 
o Number, size and location of lesions (on- site and off -site read)  
Number, size an d location of lesions detected will be recorded  for each patient . 
o Diagnostic confidence (on -site and off -site read)  
Degree of confidence will be assessed using a [ADDRESS_729074]-enhanced MRI on patient treatment plan (on- site read)  
Assessment of potential i mpact of on- site images reading, at V2 and V4, on  patient 
treatment plan.  
The 3 quantitative criteria (CNR, E% , LBR)  will be  calculated by [CONTACT_555427] [ADDRESS_729075] representative lesions (off-site read).  
o Contrast to Noise ratio (CNR)  
ð¶ð‘ð‘… =  ð‘†ð¼ð‘™ð‘’ð‘ ð‘–ð‘œð‘›âˆ’ ð‘†ð¼â„Žð‘¡
ð‘†ð·ð‘›ð‘œð‘–ð‘ ð‘’ 
where  SIlesion = Signal intensity of lesion . 
SIht = Signal intensity of healthy tissue (brain or spi[INVESTIGATOR_1831]). 
SD noise = Standard D eviation (SD) of background noise. 
o Percentage enhancement  (E%) of lesion (s) (off-site read) . 
ð¸% =  ð‘†ð¼ð‘ð‘œð‘ ð‘¡âˆ’ ð‘†ð¼ð‘ð‘Ÿð‘’
ð‘†ð¼ð‘ð‘Ÿð‘’x100  
where  SIpost = Signal intensity  of lesion  on post  injection image s. 
SIpre = Signal intensity  of lesion on pre injection images. 
o Lesion to Background Ratio (LBR)  (pre and post)   
LBR  =ð‘†ð¼ð‘™ð‘’ð‘ ð‘–ð‘œð‘›
ð‘†ð¼ð‘ 
where  SIlesion = Signal intensity of lesion . 
SIb= Signal intensity of background (healthy tissue  in brain or spi[INVESTIGATOR_1831]). 
o Overall diagnostic preference (off -site read)  
The evaluation will be performed in a global matched -pairs fashion and preference will be 
determined on a 3-point scale. Reason for preference will also be recorded.  
o Safety profile of gadopi[INVESTIGATOR_555346] (AEs) , the results of 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 8 / 79 
 
 
vital signs  measurement , the injection site tolerance  evaluation and  the clinical laboratory 
parameters (blood  samples ). 
Statistical methods  
Primary objective 1 (superiority of Paired  images versus Pre images of gadopi[INVESTIGATOR_555347] -primary criteria ) 
For gadopi[INVESTIGATOR_555334] , the difference â€œPairedâ€ - â€Preâ€ for e ach of [ADDRESS_729076] to meet the alternative hypothesis for the three co-
primary criteria in the gadopi[INVESTIGATOR_555348]: a statistically significant (one -sided pâ‰¥0.025) positive 
difference in mean score s in border delineation, internal morphology and degree of contrast 
enhancement of lesions simultaneously. 
Sample size assessment for the Primary objective 1:  
Expecting that for ea ch co -primary criteria, the difference in mean scores will be 0.35, Gutierrez et 
al. 2015, ([â€œPairedâ€ â€“ â€œPreâ€] within patient mean of lesion scores) with 1.[ADDRESS_729077] 90% power when using a single group 
superiority t -test with a 0.025 one- sided significance level.  
As 20% drop- out rate is expected, sample size increases to 250 patients with CNS lesions. 
 
Primary objective  2 non-inferiority of gadopi[INVESTIGATOR_555349] -primary criteria ): 
The Studentâ€™s t -based two-sided 95% confidence inte rvals of the difference between gadopi[INVESTIGATOR_555350] [ADDRESS_729078] 2 out  of 3 readers and for the 3 co -primary criteria  simultaneously , then non- inferiority 
between gadopi[INVESTIGATOR_555351].  
As soon as the non- inferiority is demonstrated, the superiority of the gadopi[INVESTIGATOR_555352]. No adjustment for multiplicity is needed as it is a simple 
closed testing procedure.  
Sample size for the primary objective 2:  
o Non-inferiority margin:  
For EMA, both primary objectives [ADDRESS_729079] demonstration of the superiority of Paired images with gadopi[INVESTIGATOR_555353] (objective 1). So, it can be considered as three -armed trial d
esign with unenhanced images as 
placebo as described in EMA  guideline on the choice of the non- inferiority margin . As such, it is not 
necessary to define a value for non -inferiority margin to establish that gadopi[INVESTIGATOR_555354].  
A 10% non- inferiority margin was considered clinically as an unimportant difference and therefore 
relevant to establish acceptable efficacy relative to gadobutrol (objective 2). Based on the Guerbet 
Phase IIb GDX -44-004 clinical trial results on lesion v isualization co -criteria, the mean score for 
each of the 3 co -criteria is expected to be equal to 3.5. So the margin is set to 0.35 (10%).  
o Sample size hypothesis: 
An enrollment of 200 patients is deemed necessary for the lower limit of the 95% CI to exceed  the 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 9 / 79 
 
 
non-inferiority margin set to 0.35, assuming 80% power and for each co -primary criterion, the 
expected difference in mean scores is [ADDRESS_729080] deviation of 1.75.  
If one assumed a patient drop -out rate of 20%, a minimum enrollment of 250 patients with CNS 
lesions is planned.  
Therefore, a total number of 250 patients will allow a sufficient power to meet both objectives. 
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 10 / 79 
 
 
TRIAL  FLOW CHART  
Table 1: Trial flow chart  
 
  Visit (1) V1 V2 V3 V4 V5 
Evaluation/  
procedure  
 Screening  
  
  Randomization  
1st contrast injection  
Baseline (10) Safety follow up  
Post injection  
  
2nd contrast injection  
 ([ADDRESS_729081] V2) Safety follow up  
Post injection  
 
   Time Point  â‰¤7 days  Prior  
to MRI  MRI  60Â± 
15min 1 day after V2  Prior  
to MRI  MRI  60Â± 
15min 1 day after V4  
Informed consent signature  X         
Eligibility criteria  X X    X(11)    
Demographic data  and height  X         
Medical history  including CNS  disease(12) X         
Contrast Agents  intolerance history  X         
Physical examination(2) X         
Body weight   X    X    
Concomitant treatments  X 
Pregnancy test (3) X X(3)    X    
Local creatinine and eGFR evaluation(4)  X   X X   X 
Clinical laboratory parameters (5)  X   X X   X 
Vital signs (BP, PR) (6)  X  X X X  X X 
IMP injection    X    X   
Images acquisition    X    X   
IWRS (7) X X   X X   X 
Injection -site tolerance(8)   X X X  X X X 
Adverse events (AEs)(9) X 
Procedures/Therapeutic measures  X 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 11 / 79 
 
 
 
(1) V1 can be performed on the same day as V2. MRI procedures , at V2 and V 4, should be performed on the same day as IWRS connection and contrast  agent 
injection .  
(2) Physical examination should be performed by a physician: examination of general appearance, skin, neck (including thyroi d), eyes, ears, nose, throat, lungs, 
heart, abdomen, back, lymph nodes, extremities, vascular and neurological. Information indicating the global assessment (norm al or abnormal (specify)) of the 
physical examination should be recorded on source documentati on. 
(3) Urine pregnancy test (if applicable) is to be done on site. At V2 and V4, results must be available prior to IWRS connection and administration of IMP . In case 
V1 and V2 are performed on the same day, only one pregnancy test is required.  
(4) At V2 and V4, e GFR is to be evaluated locally, and results must be available prior to IWRS connection and administration of IMP.  Starting at V3, change in 
local serum creatinine result should be checked as per ESUR guidelines (see section  7.2.10) . The same local methods of serum creatinine dosage and eGFR 
calculation should be used throughout the trial  for a same patient.  
(5) Clinical laboratory parameters will be analysed by [CONTACT_27671]:  haematology and biochemistry , see section  8.5 for details  
(6) Vital signs: BP: blood pressure (supi[INVESTIGATOR_555355] ), PR: Pulse  Rate 
(7) IWRS: connection should be done at each trial visit and in case of screening failure or premature d iscontinuation  
(8) Injection -site tolerance (pain, eruption, extravasation, inflammation, or other)  is to be  assessed during the injection, 60  Â± [ADDRESS_729082] injection.  
(9) AEs occurring during the time of the patientâ€™s participation in the trial, must be reported and followed, unless they meet the following definition: the events 
which occur before the first IMP administration, and which are not serious and  not related to the trial procedures can  be recorded as medical history upon the 
investigat orâ€™s judgement.  Procedures/therapeutic measures for AE are also to be reported . 
(10) All the assessments performed prior to the first MRI at V2 will be considered as baseline value. 
(11) Some non -inclusion criteria must be checked again at V4 (see section 4.2). 
(12) In case brain metastasis is the trial disease, the corresponding  primary cancer  will be reported in medical history  
 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 14 / [ADDRESS_729083]  Computed Tomography 
E%  Percentage enhancement of lesion 
eGFR   estimated Glomerular Filtration Rate  
EMA   European Medicine Agency 
ESUR   European Society of Urogenital Radiology 
FAS  Full Analysis Set  
FDA  Food and Drug Administration 
GBCA   Gadolinium Based Contrast Agent 
GCP   Good Clinical Practice  
Gd  Gadolinium 
GRE   Gradient Echo 
IBR  Independent Blinded Reader 
ICF  Informed Consent Form 
ICH  International Conference on Harmonization 
ID  Identification  
IEC  Independent Ethics Committee 
IMP  Investigational Medicinal Product  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 15 / [ADDRESS_729084] Characteristics 
SOC   System Organ Classes  
SS  Safety Set  
SPS  Screened Patient Set  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TEAE   Treatment Emergent Adverse Event  
TSE  Turbo Spin Echo 
WBCs   White Blood Cells 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 16 / 79 
 
 
TABLE OF CONTENTS  
PROTOCOL SYNOPSIS  ........................................................................................................................ 2 
TRIAL FLOW CHART  ........................................................................................................................ 10 
TRIAL DIAGRAM  ............................................................................................................................... 12 
SIGNATURE [CONTACT_1783]  ............................................................................................................................. 13 
ABBREVIATIONS  ............................................................................................................................... 14 
1 INTRODUCTION  ........................................................................................................................ 22 
1.1 Trial Rationale  ....................................................................................................................... 22 
1.2 Back ground ........................................................................................................................... 22 
1.3 Benefit/Risk Assessment  ....................................................................................................... 23 
2 TRIAL  OBJECTIVES  .................................................................................................................. 24 
2.1 Primary Objectives  ................................................................................................................ 24 
2.2 Secondary Objectives  ............................................................................................................ 24 
3 TRIAL DESCRIPTION ................................................................................................................ 25 
3.1 Protocol Design  ..................................................................................................................... 25 
3.2 Justification for dose ............................................................................................................. 26 
3.3 Trial Duration  ........................................................................................................................ 26 
3.3.1  Duration of patientâ€™s participation ................................................................................. 26 
3.3.2  End of trial  ..................................................................................................................... 26 
3.4 Interim Analysis  .................................................................................................................... 26 
3.5 Trial Committee(s)  ................................................................................................................ [ADDRESS_729085](s) Description  ................................................................. [ADDRESS_729086](s) Allocation / Randomization  ................................................ [ADDRESS_729087] Management  ................................................................... 32 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 17 / [ADDRESS_729088](s) and Other Trial Products  .................................................... [ADDRESS_729089](s) Compliance and Accountabi lity .................................................................. 32 
6 CONCOMITANT MEDICATIONS / PROCEDURES  ............................................................... 33 
6.1 Concomitant Medications  ...................................................................................................... 33 
6.1.1  Concomitant Medications of Special Attention  ............................................................. 33 
6.1.2  Prohibited Concomitant Medications ............................................................................ 33 
6.2 Concomitant Procedures  ........................................................................................................ 33 
7 EVALUATION CRITERIA ......................................................................................................... 34 
7.1 Primary Criteria (off- site read)  .............................................................................................. 35 
7.1.1  Primary criteria 1: lesion visualization criteria for gadopi[INVESTIGATOR_555334]- enhanced MRI 
compared to unenhanced MRI (off- site read)  ............................................................................... 35 
7.1.2  Primary criteria 2: Lesion visualization criteria for gadopi[INVESTIGATOR_555356] (off- site read).  ............................................................................................................. 36 
7.2 Secondary Criteria ................................................................................................................. 36 
7.2.1  Lesion visualization criteria for gadopi[INVESTIGATOR_555357] (off -site read) 
for FDA only.  ............................................................................................................................... [ADDRESS_729090] 
images  36 
7.2.3  Lesion visualization (on- site read)  ................................................................................ 37 
7.2.4  Technical adequacy of images (on -site and off -site read)  ............................................. 37 
7.2.5  Number, size and location of lesions (on- site and off -site read)  ................................... 37 
7.2.6  Diagnostic confidence (on- site and off -site read)  .......................................................... [ADDRESS_729091] -enhanced MRI on patient treatment plan (on- site) .......................... [ADDRESS_729092] to Noise Ratio (CNR), Percentage Enhancement (E%) of lesion(s), lesion to 
Background Ratio (LBR) (off -site)............................................................................................... 39 
7.2.9  Overall diagnostic preference (off -site read).  ................................................................ 39 
7.2.10  Safety profile of gadopi[INVESTIGATOR_555337] (on- site).  ............................................... 40 
8 TRIAL SCHEDULE AND PROCEDURES  ................................................................................ 41 
8.1 Trial Schedule  ........................................................................................................................ 41 
8.1.1  Screening Visit â€“ Visit 1 â€“ Day ( -7) to Day 0 ............................................................... 41 
8.1.2  Imaging/Randomization Visit â€“ 1st MRI â€“ Visit 2 â€“ Day 0  ........................................... 42 
8.1.3  Saf
ety Visit â€“ Visit 3 â€“ [ADDRESS_729093] visit 2 ..................................................................... 43 
8.1.4  Imaging Visit â€“ Visit 4 â€“ 2nd MRI â€“ [ADDRESS_729094] V2 ................................ 43 
8.1.5  Safety Visit â€“ Visit 5 â€“ [ADDRESS_729095] Visit 4  .................................................................... 44 
8.2 Imaging Characteristics  ......................................................................................................... 45 
8.2.1  Equipment ..................................................................................................................... 45 
8.2.2  Imagin g protocol ........................................................................................................... 45 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 18 / 79 
 
 
8.3 On-Site Reading of Images  ................................................................................................... 46 
8.4 Off-Site Reading of Images  ................................................................................................... 46 
8.4.1  Manuals and Supplies  .................................................................................................... 46 
8.4.2  Site Qualification  ........................................................................................................... 46 
8.4.3  Receipt and Tracking of Images .................................................................................... 47 
8.4.4  Image Processing and Quality Check  ............................................................................ 47 
8.4.5  Independent Blinded Readers Training ......................................................................... 47 
8.4.6  Image Randomization  .................................................................................................... 47 
8.4.7  Blinded Assessment of Images ...................................................................................... 47 
8.4.8  Inter & Intra -reader Variability Assessment  ................................................................. 48 
8.4.9  Lesion tracking/Matching  .............................................................................................. 48 
8.4.10  Image Archive and Final Deliverables  .......................................................................... 48 
8.5 Non Imaging Central procedures: central laboratory ............................................................ 48 
9 SAFETY REPORTING  ................................................................................................................ 50 
9.1 Adverse Event  ....................................................................................................................... 50 
9.1.1  Definition of Adverse Event  .......................................................................................... 50 
9.1.2  Collection and recording of Adverse Events ................................................................. 50 
9.1.3  Description of Adverse Events ...................................................................................... 51 
9.2 Serious Adverse Event  .......................................................................................................... 53 
9.2.1  Definition of Serious Adverse Event  ............................................................................. 53 
9.2.2  Reporting Serious Adverse Events (SAE)  ..................................................................... [ADDRESS_729096]  ................................................................................ 56 
9.3.4  Any suspi[INVESTIGATOR_555358] ................................ 56 
9.4 Other important safety issue / new fact  ................................................................................. 56 
9.5 Unblinding Procedures .......................................................................................................... 57  
10 SC
REEN FAILURE AND PREMATURE DISCONTINUATION ............................................. 58 
10.1  Screen failure  ......................................................................................................................... 58 
10.2  Premature Discontinuation of the trial per Guerbet Decision  ............................................... 58 
10.3  Premature discontinuation  ..................................................................................................... 58 
10.4  Reasons for patientâ€™s screening failure and premature d iscontinuation ................................ 58 
10.5  Enrolment of additional patient  ............................................................................................. 59 
11 STATISTICAL CONSIDERATIONS  ......................................................................................... 60 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 19 / 79 
 
 
11.1  Statistical Method  .................................................................................................................. 60 
11.2  Sample Size  ........................................................................................................................... 60 
11.3  Planned Analysis ................................................................................................................... 62 
11.3.1  Disposition of patients ................................................................................................... 62 
11.3.2  Data Sets Analyzed ........................................................................................................ 62 
11.3.3  Protocol Deviations ....................................................................................................... 63 
11.3.4  Demographics and Baseline Characteristics  .................................................................. 63 
11.3.5  Compliance .................................................................................................................... 63 
11.3.6  Efficacy Analysis ........................................................................................................... 63 
11.3.7  Adverse Event  ............................................................................................................... 66 
11.3.8  Laboratory data .............................................................................................................. 67 
11.3.9  Other safety observations  .............................................................................................. 67 
11.4  Specific Statistical Analytical considerations ........................................................................ 67 
11.4.1  Adjustments for Covariates ........................................................................................... 67 
11.4.2  Handling of Dropouts or Missing Data ......................................................................... 67 
11.4.3  Interim Analyses ............................................................................................................ 67 
11.4.4  Multicenter Trial  ............................................................................................................ 68 
11.4.5  Multiple Comparisons/Multiplicity  ............................................................................... 68 
11.4.6  Use of an "Efficacy Subset" of patients  ......................................................................... [ADDRESS_729097]/Independent Ethics Committee and Regulatory/Competent 
Authorities ......................................................................................................................................... 71 
13.3  Patient Informed Consent ...................................................................................................... 71 
13.4  Trial Records and Archiving ................................................................................................. 72 
14 QUALITY CONTROL / QUALITY ASSURANCE  ................................................................... [ADDRESS_729098] Access to Source Data/Documents  ............................................................................. 73  
14.2  Clinic
al Monitoring  ............................................................................................................... 73 
14.3  Clinical Data Handling  .......................................................................................................... 73 
14.3.1  Data Reported in the eCRF  ............................................................................................ 73 
14.3.2  Data Reported in the clinical eCRF according to patient Status  ................................... 74 
14.3.3  Data Management System  ............................................................................................. 74 
14.4  Audits and Inspections .......................................................................................................... 74 
15 PUBLICATIONS RULES  ............................................................................................................ 75 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 20 / [ADDRESS_729099] OF TABLES  
Table 1: Trial flow chart  ........................................................................................................................ 10 
Table 2: overview of imaging trial criteria  ............................................................................................ 34 
Table 3: images sets per patient ............................................................................................................. 34 
Table 4: imaging diagnosis  .................................................................................................................... 38 
Table 5: Collection and reporting of AEs throughout and after the trial ............................................... [ADDRESS_729100] OF FIGURES  
Figure 1:trial  diagram  ........................................................................................................................... 12 
 
 
   
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 21 / 79 
 
 
AMENDMENT  
Not Applicable 
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 22 / [ADDRESS_729101] A gents (GBCAs ) consist of the active substance gadolinium (Gd) and a 
chelating agent. They can be categorized by [CONTACT_555428] (ionic or non-ionic). In vitro  experiments have shown 
that the macrocyclic compounds are the most stable, with an undetectable re lease of Gd3+ ions under 
physiological conditions. 
Gadopi[INVESTIGATOR_555334] (P03277) is a new chemical entity discovered and developed by [CONTACT_555429]. It is a non-
ionic macrocyclic gadolinium (Gd) complex, of high kinetic stability, intended to be used in human, 
by [CONTACT_33980] (IV) administration, as a contrast agent for M agnetic R esonance I maging (MRI).  
The ability of gadopi[INVESTIGATOR_555359] a MRI contrast agent has been demonstrated by [CONTACT_555430] -fold 
higher T1 relaxivity compared to other available Gd -based contrast ag ents (GBCA). A proof of 
concept has been obtained for the efficacy of gadopi[INVESTIGATOR_555360] a MRI contrast agent for central nervous 
system (CNS) imaging in a model of brain tumor implanted in rats as well as during the phase IIa clinical trial. The safe and lowest effective clinical dose identified in phase IIb trial is  0.05 mmol/kg 
body weight (BW) based on comparison with gadobenate dimeglumine (MultiHance
Â®) for the 
contrast- to-noise ratio (CNR) assessed as primary endpoint.  
One phase I/IIa trial and one phase IIb trial have been completed, with 304 patient s exposed to 
gadopi[INVESTIGATOR_555334]. On the basis of the extensive nonclinical study program and the PK/ clinical safety data available from 
phase I/IIa and phase IIb trials , it is  considered that there are sufficient guarantees to ensure the safety 
of gadopi[INVESTIGATOR_555361] (from 2 to 17 years) patients at a single dose .  
 
At the launch of the phase III program and based on the initial clinical studies, the administrations of 
the gadopi[INVESTIGATOR_555362]. More details on the safety are provided in the investigatorâ€™s 
brochure in force that is the reference safety information for the gadopi[INVESTIGATOR_555334]. Likewise, the SmPC is 
the reference safety informati on for gadobutrol. 
 
1.[ADDRESS_729102] been used extensively in a large range of indications, particularly MRI  
examinations of Central Nervous System (CNS). Contrast enhancement has enabled improving tissue 
contrast and lesion characterization and more sensitive detection of even very small lesions. Contrast -
enhanced MRI of brain lesions also plays a vital role during the post -therapeutic or in tervention phase 
in determining treatment response: ea rly identification of the lack of treatment efficacy can facilitate 
selection of an alternative therapeutic approach, potentially improving patient  outcomes 
Pathologies of the CNS represent the most important indication in MR I. It is a well -established 
technique and more than 50% of CNS MR examinations are performed after intravenous (IV) injection 
of a GBCA. For MR Imaging of CNS , the GBCAs already commercialized exhibit a range of r1 and r2 
relaxivi ty values providing their efficacy at a clinical dose at 0.1 mmol/kg  BW. Optimal detection and 
characterization of CNS lesions on contrast -enhanced T1- weighted MR imaging depends as much on 
the contrast agent used as on the sequence parameters applied for image acquisition. The increased R1 
relaxivity leads to increased signal intensity enhancement and thus significantly improved lesion 
visualization and better depi[INVESTIGATOR_555363] [1-8]. High relaxivity 
GBCA may potentially enable earlier detection of small cerebral  or spi[INVESTIGATOR_158444], or detect more 
tiny lesions which may be overlooked by [CONTACT_555431]. 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 23 / 79 
 
 
1.3 Benefit /Risk Assessment  
The results of the clinical trial phase IIa suggest that gadopi[INVESTIGATOR_555364] a 
contrast agent for MRI and is safe an d well tolerated in patients with brain lesions up to a dose of 0.2 
mmol/kg . The phase IIb trial  demonstrated the efficacy of gadopi[INVESTIGATOR_555365]. 
 
   
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 24 / 79 
 
 
2 TRIAL  OBJECTIVES  
As the trial is a multi -regional one and in order to meet with the respective requirements of regulatory 
authorities within one single protocol, trial objectives are presented with reference to the regulatory 
authorities. . 
2.1 Primary Objectives 
Primary objective 1:  
o To demonstrate the superiority of gadopi[INVESTIGATOR_555334]- enhanced MRI at 0.05 mmol/kg body weight 
(BW) compared to unenhanced MRI for patient referred for contrast- enhanced MRI of CNS, 
in terms of 3 lesion visualization co- primary criteria ( border delineation, internal morphology 
and degree of contrast enhancement) using the patient as his/her own control. 
Primary objective 2: 
o To demonstrate the non-inferiority of gadopi[INVESTIGATOR_555335] 0.05 mmol/kg compared to gadobutrol at 
0.1 mmol/kg in terms of 3 lesion visualization co- primary criteria (border delineation, internal 
morphology, degree of contrast enhancement) for patient referred for contrast- enhanced MRI 
of CNS.  
For FDA, the primary objective 1 is to be achieved. The primary objective 2 will serve as one of the 
secondary objectives.  
For EMA, both primary objectives 1 and 2 are to be achieved. 
 
2.2 Secondary Objectives  
o To demonstrate the non- inferiority of gadopi[INVESTIGATOR_555366]  3 
lesion visualization co -primary criteria (border delineation, internal morphology, degree of 
contrast enhancement) for patient referred for contrast- enhanced MRI of the CNS  (idem 
primary objective 2, considered as secondary objective for FDA).   
o To assess the following parameters with gadopi[INVESTIGATOR_555337]  
ïƒ¼ lesion visualization assessment by [CONTACT_1697]  
ïƒ¼ Improvement in lesion visualization scores  at patient -level  
ïƒ¼ Technical adequacy of images 
ïƒ¼ Number, size and location of lesions  
ïƒ¼ Diagnostic confidence  
ïƒ¼ Impact of contrast-enhanced MRI on patient treatment plan   
ïƒ¼ Contrast to Noise Ratio (CNR)   
ïƒ¼ Percentage enhancement (E%) of lesion (s)  
ïƒ¼ Lesion to Background Ratio (LBR)  
ïƒ¼ Overall diagnostic preference  
o To assess the safety profile of gadopi[INVESTIGATOR_555367]. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 25 / 79 
 
 
3 TRIAL  DESCRIPTION 
3.1 Protocol Design  
The trial ha s a prospective, multi- center, randomized, double -blind, controlled and cross- over design . 
The IMPs used during the trial are gadopi[INVESTIGATOR_555368]. 
The primary criteria  1 will compare gadopi[INVESTIGATOR_555334]- enhanced MRI (pre + post images = paired ima ges) 
to unenhanced MRI (pre images), using the patient as h is/her own control.  
The primary criteria  2 will compare gadopi[INVESTIGATOR_555334] -enhanced MRI (paired images) to gadobutrol -
enhanced MRI (paired images).  
Patients, once informed consent form (ICF) signed, will  perform a screening visit (V1) to confirm trial 
eligibility, then will be randomized in the trial to determine the order of IMP injection. Each of the 2 
MRI visits (V2 and V4)  will be followed by a safety visit (V3 and V5) performed 1 day after the MRI 
visit. 
Two MRIs will be obtained for each patient: gadopi[INVESTIGATOR_555369] l-enhanced MRI and gadobutrol -enhanced 
MRI (see Figure 1) , however the nature of the contrast agent s injected at V isit 2 and at Visit 4 will be 
randomly assigned by [CONTACT_10966]. 
The investigator and the patient will remain blinded to IMPs allocation (nature of the IMPs and order 
of the IMP injection). A designated unblinded site staff member will be in charge of preparation and 
administration of the IMPs.  
The randomization scheme will allocate patient s in a 1:[ADDRESS_729103] experienced in 
MRI of CNS will be appointed at the start of the trial to read all images of  patients included at the site  
(on-site read). 
In addition, images will be evaluated by [CONTACT_555421] a centralized 
manner. All images will be sent to a core laboratory, which  will prepare the images for evaluation.  
The blinded image evaluations (off-site read) will be performed by 3 independent blinded radiologists 
for the reading of random images reading and by 3 additional independent blinded radiologists for the 
global pairs assessment. An imaging electronic Case Report Form (eCRF) will be used to ensure that  
the images are properly aligned and to ensure that all necessary data for the trial purpose are documented by [CONTACT_555422]. 
To allow exact matching of lesions between imaging modalities (Pr e and Paired), between the two MR 
examinations with gadopi[INVESTIGATOR_555337], and among [ADDRESS_729104] 
(lesion tracker) will perform lesion tracking, separate from the image evaluations. by [CONTACT_555432].   
The IWRS  will be used to randomize order of contrast agents to be injected, to allocate IMPs, to 
calculate the volume of IMP to be administered based on the body weight and to record patient â€™s 
visits . 
During the trial, the safety will be monitored and assessed based on the reporting of adv erse events 
(AEs) , the results of vital signs  measurement , the injection site tolerance  evaluation and the clinical 
laboratory parameters (blood  samples). 
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 26 / 79 
 
 
3.2 Justification for dose  
Based on Phase IIb results, gadopi[INVESTIGATOR_555370] 0.05mmol/kg BW, is deemed to be as efficient as all 
other available GBCAs at  clinical dose of 0.1mmol/kg BW. It will be investigated for diagnos tic 
efficacy  in terms of lesion visualization  in patients with CNS pathologies.  
Gadobutrol will be used, as an active  comparator, at its standard approved dose of 0.1 mmol/kg BW. 
3.3 Trial  Duration 
3.3.1 Duration of patient â€™s participation  
Minimum trial duration for patient s: 4 days (if V1 and V2 done on the same day ) and the second MRI 
is done [ADDRESS_729105] one. 
Maximum trial duration for patients: [ADDRESS_729106] one.  The trial includes a maximum of 5 visits: 
- One screening visit (V1) up to 7 days prior to inclusion ( V1 could be done on the same day as 
the randomization  visit  (V2)  if all the inclusion/non-inclusion criteria are met).  
- Two sequential imaging visits (V2 and V4, minimum interval 2 days and up to 14 days): each 
visit will consist of a gadopi[INVESTIGATOR_555371].  
- Two safety visits (V3 and V5): [ADDRESS_729107] 
been reviewed by [CONTACT_555425].  
The patientâ€™s participation is defined as the period from the screening visit (ICF signature) to the last 
trial visit.  
 
3.4 Interim A nalysis  
Not applicable  
 
3.5 Trial  Committee(s)  
Not applicable (see Section  12). 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 27 / [ADDRESS_729108] meet all these inclusion criteria.  
1. Female or male adult patient (patient having reached legal majority age).  
2. Patient presenting  with known or highly suspected CNS lesion(s) with focal areas of 
disrupted Blood Brain Barrier  (BBB) (e.g., primary  and secondary tumors ) based on 
results of a previous imaging procedure such as Computed Tomography (CT) or MRI, 
which should have been performed within  [ADDRESS_729109]- enhanced MRI examination for the purpose of the trial.  
4. If the patient  was treated (either with radiation, surgery, biopsy or other re levant 
treatments) between previous imaging evaluation and trial MRI, there should still be a 
high suspi[INVESTIGATOR_555340](s) on the basis of available clinical information.  
5. Patient able and willing to participate in  the trial. 
6. Patient having read th e information and having provided his/her consent to participate in 
writing by [CONTACT_555433]. 
7. Patient affiliated to national health insurance according to local regulatory requirements.  
 
4.[ADDRESS_729110] not be included in 
the trial : 
1. Patient presenting extra cranial lesions and/or extra -dural lesions.  
2. Patient presenting with  an acute relapse of multiple sclerosis as qualifying CNS lesion . 
3. Patient  presenting with known class III/IV congestive heart failure according to the New 
York Heart Association classification (NYHA).  
4. Patient  having received any investigational medicinal prod uct within [ADDRESS_729111] agent (MRI or CT) within [ADDRESS_729112] administration. 
8. Patient expected/scheduled  to have any treatment or medical procedure (e.g. 
chemotherapy, radiotherapy, biopsy or surgery etcâ€¦) that may impact the aspects of the imaged lesions between the 2 MRI examinations. (Patients under corticosteroids and/ or 
maintenance chemotherapy with a stable  dose at the time of screening visit and throughout 
the trial can be included).   
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 28 / [ADDRESS_729113] condition (medical, psychological, social or 
geographical) that would compromise the patient â€™s safety or her/his ability to part icipate 
in the trial.  
10. Patient  unlikely to comply with the protocol, e.g. uncooperative attitude, inability to return 
for follow -up visits and/or unlikelihood of completing the trial.  
11. Patient  related to the investigator or any other trial staff or relative directly involved in the 
trial conduct.   
Non-inclusion criteria to be checked at V1, V2 and V4: 
12. Patient  presenting with acute or chronic renal insufficiency, defined as an estimated 
Glomerular Filtration Rate (eGFR) < 30 mL/min/1.[ADDRESS_729114] -feeding female patient (a female patient of childbearing potential or 
with amenorrhea for less than [ADDRESS_729115] be using a medically approved contraception method* 
until the last trial visit) . 
14. Patient  with known contra -indication(s) to the use or with known sensitivity to one of the 
products under investigation or to other GBCAs  (such as hypersensitivity, P ost contrast 
acute kidney injury).  
* medically approved contraception methods include: abstinence (defined as refraining from 
heterosexual intercourse during the entire trial), female sterilization (sterilization methods include 
hysterectomy, bilateral sa lpi[INVESTIGATOR_15559]),  combined (estrogen and 
progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen -only hormonal contraception associated with inhibition of  
ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone -releasing 
system (IUS), bilateral tubal occlusion, vasectomised partner (vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner of the female patient and 
that the vasectomised partner has received medical assessment of the surgical success.)  
Periodic abstinence ( calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and lactational amenorrhoea method (LAM) are not acceptable  
methods of contraception. Female condom and male condom should not be used together. 
The diagnosis obtained from previous (qualifying) imaging examinations will be considered as 
medical history to assess inclusion criteria. All the trial efficacy analyses will be only based on the 
images obtained through the trial MRI. 
4.3 Patient  Identification  
After having signed  the written informed consent patients will be allocated a unique Identification 
Number ( Patient  ID).  
Any patient  who has signed an informed consent will be considered as a â€˜screenedâ€™ patient . 
This Patient  ID will contain 8 digits: the first three digits corresponding to the country number (code 
ISO 3166 -1 numeric) the following two digits corresponding to the site number, which are attributed 
at the beginning of the trial, and the last three digits being chronologically implemented depending on 
patient  screening. The lowest screening number will correspond to the first patient screened at this site 
and the highest number to the last patient  screened.  
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 29 / [ADDRESS_729116](s) (IMP) will be manufactured, labeled, packaged and released in 
accordance with:  
- European Directive 2003/94/EC  laying down the principles and guidelines of good 
manufacturing practice in respect of medicinal products for human use and investigational 
medicinal products for human use 
- EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, EU 
Guidelines to Good Manufacturing Practice - Medicinal Products for Human and Veterinary 
Use, Annex [ADDRESS_729117] (s) Description  
5.1.[ADDRESS_729118] 1  
Name: [CONTACT_555500][INVESTIGATOR_555372]: vial of 20 ml   
Gadopi[INVESTIGATOR_555373]. Each vial contains 20 mL of solution presented as a sterile, clear,  
ready -to-use solution for injection.  
Concentration: 0.5 M 
Route and method of administration:  single intravenous ( IV) bolus injection at a recommended rate of 
2 mL/second  followed by a saline flush via manual injection or power injector. 
Dose per administration: dose /volume of gadopi[INVESTIGATOR_555374]â€™s weight at the dose of 0.05 mmol/kg BW. V olume to be injected will be rounded to 
the nearest whole number as described in section 5.6. 
Sufficient IMP must  be allocated to one patient  by [CONTACT_10966].  
Please refer to t he Investigator Brochure for more information on gadopi[INVESTIGATOR_555334]. 
 
5.1.[ADDRESS_729119] 2  
Name: [CONTACT_555501]: vial of 15 ml  
Gadobutrol is an aqueous solution. Each vial contains 15 mL of solution presented as a sterile, clear,  
ready -to-use solution for injection.  
Concentration: 1 M 
Route and method of administration: single intravenous ( IV) bolus injection at a recommended rate of 
2 mL/second followed by a saline flush via manual injection or power injector. 

 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 30 / 79 
 
 
Dose per administrat ion: dose /volume of gadobutrol to be administered will be calculated by [CONTACT_555434]â€™s weight at the dose of 0.1 mmol/kg BW . Volume to be injected will be rounded to 
the nearest whole number as described in section 5.6. 
Sufficient IMP must be allocated to one patient by [CONTACT_10966].  
Please refer to the SmPC  of gadobutrol for more information on the product. 
 
5.[ADDRESS_729120] accordance with the local regulatory specifications 
and requirements. 
The packaging and labeling of gadopi[INVESTIGATOR_555375] (or its 
designee).  
The outer packaging will be the same for both products in order to ensure the double-blind conditions. In addition to the usual and regulatory labeling for clinical studies, each IMP will have a white 
detachable sticker indicating the protocol number, IMP number, batch number and patient number . 
This label will be stuck on the patient file or trial documentation. 
IMP will consist in a box that contains one 20  ml vial of gadopi[INVESTIGATOR_555376] 15 ml vial of gadobutrol. 
In case of issue related to  IMP (damaged, broken vialsâ€¦) , a new IMP will be allocated to the p atient 
via the IWRS.  
All IMPs will be stored in a secure place, under the responsibility of the Investigator or other 
authorized individuals. The IMPs should be stored at a temperature of 25Â°C or below in the original 
package, protected from light and not frozen. 
At the time of the trial completion, all used (including empty vials) and unused IMPs should have been 
returned to Guerbet  or to the predefined location for storage before destruction. 
 
5.[ADDRESS_729121](s) Allocation / Randomization  
At visit 2, the patients will be randomly assigned to one series of 2 MRIs performed each at two trial visits separated by a wash out period of 2 days minimum  and up to 14 days. One series consists of t he 
use of gadopi[INVESTIGATOR_555334], single intravenous (IV) bolus injection, as contrast agent at visit 2  and gadobutrol, 
single intravenous (IV) bolus injection, at visit 4  and reverse order for the second series  (see Figure 
1). 
The randomization scheme will allocate patients in a 1:[ADDRESS_729122] to document in 
a separated patientâ€™s file all the unblinded information related to the IMPs and will have to complete 
dedicated restricted field in clinical eCRF pages. 
During the course of the trial, the two teams should not exchange any information regarding the IMPs (nature of IMP injected , order of administration,). The patientsâ€™ files with unblinded data should not be 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 31 / 79 
 
 
filed with the patientâ€™s medical and trial files in order to not break the blind.  The unblinded 
documentation should be stored shielded from the view of the blinded staff. An initial shipment of 
IMPs will b e sent to the investigational sites  after having received regulatory authorization(s)/ethical 
approval(s) as per local requirements. Additional shipments will be sent according to patient  
recruitment progress of a given investigational site. The site shoul d ensure to have enough IMPs 
before including a new patient. The site can log onto IWRS to know the IMPs stock status. 
IMP receipt will be acknowledged by [CONTACT_093] (or any designated person in his/her team) via 
IWRS.  
At visit 2 and visit 4, once  all the inclusion /non- inclusion criteria, including eGFR and pregnancy test 
have been checked, the site should log onto the IWRS which will allocate IMP (s) number available at 
the site . This/these IMP(s) will  correspond to the allocated treatment  arm and t o the contrast  medium 
allocated for the enhanced MRI procedure.  
In case one IMP breaks or becomes non -sterile or is not available,  or any  problem of IMP allocation 
(e.g. wrong IMP administered to the patient ), the site must immediately report the incident into IWRS 
and to Guerbetâ€™s  representative in order to ensure that all corrective action s are taken . Corrective 
actions may include transferring the IMP to quarantine to prevent fur ther IMP allocation by [CONTACT_555435]. Detailed instructions can be found in the IWRS manual 
provided to the sites.  
 
5.3.2 Double- Blind  Conditions   
To ensure that administration of the IMP is carried out under double -blind conditions, an unblinded 
team  (nurse, technician or physician) will be responsible for preparing and administrating the IMP(s). 
This person will ensure non -disclosure of information .  He /she will stick the detachable label of the 
vial into the Patient â€™s records or appropriate form. He /she will also write his/her name, date and 
signature [CONTACT_555502], and after use, he/she will close the box with a seal. 
Any dis closure relating to the nature of the contrast agent injected by [CONTACT_555436] a protocol deviation. 
Image readings of all patients will be evaluated in blinded conditions regarding the contrast agent 
injected, as described in Section  8.4. 
 
5.3.3 Individual Trial  Treatment  Unblinding  
In case of an adverse event occurring for a patient and which nature would require immediate 
knowledge of the allocated IMP, the individual trial treatment may be unblinded, if absolutely 
necessary for the safety of the patients and if unblinding impacts the management o f medical cares 
(see section  9.5).  
Conditions and procedure for breaking the code will be reviewed with the investigator and his/her team during the initiation visit.  
The persons authorized to unblind trial product during t he trial usually are: the investigators and 
Guerbet Pharmacovigilance physician/officer  and European Qualified Person for Pharmacovigilance  
(EU-QPPV) .   
If the Clinical Project Manager receives an external request for unblinding (Authorities, health care professionals taking care of the patient, etc.), he/she must inform Guerbet Pharmacovigilance 
physician/officer.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 32 / 79 
 
 
If the investigator and Guerbet Pharmacovigilance physician/officer unblind the trial product  via the 
IWRS , he/she must inform the Clinical Project Manager as soon as possible but shall not reveal the 
nature of the trial product in order to protect as much as possible the double- blind design of the trial.  
Unblinding must be documented by [CONTACT_555437]â€™s identification number, age and sex , the 
date, time and the reason for unblinding, the identity of the person who performed the unblinding.  
Please refer to Section 9.[ADDRESS_729123], or other personnel allowed to store and dispense IMP (s) is 
responsible for ensuring that the IMP used in the clinical trial is securely maintained as specified by 
[CONTACT_555438].  
Any quality issue noticed with the receipt or use of an IMP (deficient IMP in condition, appearance, 
pertaining documentation, labeling, expi[INVESTIGATOR_5695], etc.) should be promptly notified to Guerbet , who will 
initiate a complaint procedure. 
Under no circumstances shall the investigator supply IMP to a third party, allow s the IMP to be used 
other than as directed by [CONTACT_555439], or dispose of IMP in any other manner. 
 
5.[ADDRESS_729124](s)  and Other Trial  Products  
Not applicable  
 
5.[ADDRESS_729125] (s) Compliance and Accountability  
An unblinded third party, hospi[INVESTIGATOR_98341], or other allowed personnel , designated by [CONTACT_1275], will keep accurate records of IMPs  accountability at site level as well as accurate records 
of the batch numbers and quantities of the IMP given to each patient .  
The dosing information will be recorded in individual patient â€™s records. When protocol required IMP 
administration conditions are not followed, reason(s) will be given and recorded by [CONTACT_555440]â€™ source document and clinical eCRF . 
The volume (mL) of IMP to be injected to the patients will be determined by [CONTACT_10966]. The volume will 
be automatically rounded by [CONTACT_555441]: 
â€¢ If decimal is  < 0.5, volume is rounded to the inferior value (e.g.: from 15.4 mL to 15 mL) 
â€¢ If decimal is  â‰¥ 0.5, volume is rounded to the superior value (e.g.: from 15.8 mL to 16 mL)  
  
. 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 33 / 79 
 
 
6 CONCOMITANT MEDICATIONS  / PROCEDURES  
6.1 Concomitant Medications  
Any medication, including contraception, homeopathic products, pre medication, over-the-counter 
medications, as well as prescription drugs, on- going at the time of patient â€™s informed consent signed 
or administered during the trial will be recorded in the patientâ€™s medical file  and clinical  electronic 
Case Report Form (eCRF ). The following information must be provided:  
- Drug (brand name [CONTACT_18058])  
- Route of administration 
- Purpose (medical history/trial disease/AE/pre -medication/contraception/prophylaxis) 
- Indication  
- Start/end period: before first administration, between first and second administration, after 
second  (last) administration, ongoing at the end of the trial.  
 
6.1.[ADDRESS_729126] A gents, and 
therefore, no specific hydration procedure is defined in this protocol. Nonetheless, whenever possible, 
the patient should be encouraged to drink water and other non- alcoholic fluids liberally before and 
after the injection.  
According to current knowledge, there is no other concomitant treatment of special attention in that 
trial. However warnings and precautions for use of the concomitant treatment s taken by [CONTACT_555442]. 
In addition, no significant change should occur in any treatment or medical procedure (e.g. 
chemotherapy, radiotherapy, biopsy or surgery etcâ€¦) which may impact the appearance of brain 
lesion between the 2 MRI examinations. However, patients under corticosteroids and/or maintenance 
chemotherapy with a stable  dose at the time of screening visit and throughout the trial can be included. 
 
6.1.[ADDRESS_729127] agent (MRI or CT) within [ADDRESS_729128] administration are prohibited. 
 
6.2 Concomitant Procedures  
Not applicable  
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 34 / 79 
 
 
7 EVALUATION CRITERIA 
An overview of the imaging trial criteria evaluated by [CONTACT_093] (INV)  and the Independent 
Blinded Readers (IBR) is provided in the  Table 2  below:  
Table 2 : overview  of imaging trial criteria  
Images  Pre  
gadopi[INVESTIGATOR_555377] - 
pairs  
Lesion visualization  INV/IBR  INV/IBR  INV/IBR  INV/IBR   
Technical adequacy of  
images  INV/IBR  INV/IBR  INV/IBR  INV/IBR   
Number, Size and 
location of lesions  INV/IBR  INV/IBR  INV/IBR  INV/IBR   
Diagnostic confidence   INV/IBR  INV/IBR  INV/IBR  INV/IBR   
Impact of contrast -
enhanced MRI on 
patient treatment  plan   INV INV  
Contrast to Noise ratio 
(CNR)    IBR IBR  
Percentage enhancement 
(E%)  of lesion(s)    IBR IBR  
Lesion to b ackground  
ratio (LBR)    IBR IBR  
Overall diagnostic  
preference      IBR 
IBR: independent blinded reader (off -site); INV: investigator (on -site)  
The image s sets evaluated per patient are described in the Table 3  below: 
Table 3 : images sets per patient  
Image Set Number  Type  
1a Pre images =  unenhanced MRI before gadopi[INVESTIGATOR_555378]  
2a Pre images = u nenhanced MRI before gadobutrol  injection  
1b Paired images  = combined unenhanced and gadopi[INVESTIGATOR_555334] -enhanced MRI  
(pre+post images)  
2b Paired images  = combined unenhanced and gadobutrol -enhanced MRI  
(pre+post images)  
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 35 / 79 
 
 
7.1 Primary Criteri a (off-site read)  
7.1.1 Primary criteria 1 : lesion  visualization criteria for gadopi[INVESTIGATOR_555334]- enhanced MRI  
compared to unenhanced MRI (off- site read)  
The l esion visualization criteria is based on 3 co- primary criteria: border delineation, internal 
morphology and degree of contrast enhancement , assessed  on the images acquired during the MRI 
performed with gadopi[INVESTIGATOR_555334]. 
The IBR will record each of the [ADDRESS_729129] enhancing lesions should be prioritized. 
The evaluation will be performed on Pair ed images ( images set 1b) versus Pre images (images set 1a) 
using a 4 -point scale as described below : 
o Border delineation:  
Delineation of the lesion border is defined as the distinction of lesion from surrounding tissues, 
structures, or edema; and the detection of extent of the lesion (for extra -axial lesions, this pertains to 
the definition of the space in which the lesion is present, and for intra -axial lesions, it pertains to the 
invasion of white matter, gray matter, or both; the neuroanatomical distribution of the lesion; and its mass effect). This criterion will be assessed through the following scale:  
1 = none: no or unclear delineation 2 = moderate: some areas of clear delineation but also with some significant areas of 
non-distinct delineation  
3 = good: almost clear but not complete delineation 
4 = e xcellent: border outline is sharp with clear and complete delineation  
 
o Internal morphology:  
Internal morphology of the lesion includes an identification of lesion architecture and the intra -lesion 
featu res such as necrosis, hemorrhage and vascularity. This criterion will be assessed through the 
following scale: 
1 = poor: poorly seen 2 = moderate: majority of lesion is poorly seen but with minor parts of lesion visible 
3 = good: majority of lesion is clearly seen but with minor parts of lesion invisible 
4 = excellent: lesion is well seen and can see â€œthroughâ€ lesion to observe any complex  
areas of necrosis or hemorrhage or cyst formation  
 
o Degree of contrast enhancement:  
This criterion will be a qualitative assessment (not based on signal intensity measurement) according 
to the following scale:  
1 = no: no enhancement  
2 = moderate: weakly enhanced  
3 = good: clearly enhanced 4 = excellent: clearly and brightly enhanced  
 
The mean  of scores for each of the 3 lesion visualization co- criteria will be calculated as follows:  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 36 / 79 
 
 
 Mean  of scores = score of lesion 1 + score of lesion 2  (if any) + score of lesion 3 (if any ) 
divided by [CONTACT_555426] (up to [ADDRESS_729130] representative lesions) .  
For each reader, only matching lesion between paired images and pre images will be considered for 
the purpose of the primary criteria 1 evaluation.  
For each reader, if the MR images are not assessable or if no matching lesion is identified betw een 
Paired images and Pre images, then the patient will not be included in the primary criteria 1 evaluation. 
The mean of scores for each of the lesion visualization co - primary criteria 1 will range from 1 to 4.  
 
7.1.2 Primary criteria 2: Lesion visualization criteria for gadopi[INVESTIGATOR_555379] (off- site read).  
Same as primary criteria  1, the lesion visualization criteria is based on 3 co- primary criteria: border 
delineation, internal morphology and degree of contrast enhancement assessed on the images acquired 
during the MRI performed with gadopi[INVESTIGATOR_555380]. 
The IBR will record each of the [ADDRESS_729131] representative lesions, on Paired 
images ( images set 1b ) performed with gadopi[INVESTIGATOR_555381] ( images set  2b) performed 
with gadobutrol using a 4- point scale .  
Definitions of each co -primary criteria  and score calculation are provided in section  7.1.1.  
For each reader, only matching lesion between paired images of gadobutrol and gadopi[INVESTIGATOR_555382] 2 evaluation.  
For each reader, if the MR images are not assessable or if no matching lesion is identified on paired 
images between gadopi[INVESTIGATOR_555337], then the patient will not be included in the primary 
criteria 2 evaluation.  
The mean of scores for each of the lesion visualization co - primary criteria 1 will range from 1 to 4. 
 
7.2 Secondary Criteria  
All secondary criteria will be evaluated for gadopi[INVESTIGATOR_555337]. 
7.2.1 Lesion vi sualization  criteria for gadopi[INVESTIGATOR_555357] (off-site 
read) for FDA only. 
The criteria is the same as described in section 7.1.2. 
 
7.2.[ADDRESS_729132] images  
Improvement in lesion visualization scores at patient- level is based on 3 co- primary criteria:  border 
delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopi[INVESTIGATOR_555337]. 
For each contrast agent on Pre and Paired images and for the 3 co -primary criteria, the l esion score is 
calculated and compared between Pre and Paired images. If the lesion score of Paired images is greater 
than those of Pre images then the Paired image will be classified as â€œBetterâ€. If the mean score of 
Paired images is equal or less than those of Pre images then the Paired image will be classified as â€œNot Betterâ€.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 37 / 79 
 
 
 
7.2.3 Lesion visualization  (on-site read)  
The l esion visualization criteria is based on 3 co- criteria: border delineation, internal morphology and 
degree of contrast enhancement  assessed on the images acquired during the MRI performed with 
gadopi[INVESTIGATOR_555337]. 
The investigator (radiologist)  will record each of the [ADDRESS_729133] 
representative lesions, on Pre and Paired images (images set 1a, 2a, 1 b, and 2b) using a 4 -point scale. 
The 3 co- criteria definition are listed in section 7.1.1  
 
7.2.4 Technical adequacy of images (on-site and off- site read)  
For each contrast agent , images will be evaluated as technically adequate for diagnosis using a 4-point 
scales and as assessable or not  by [CONTACT_555443] .  
The technical adequacy of images will be rated on a 4 point scales:  
1 = non diagnostic 
2 = poor 
3 = fair  
4 = good  
Images should be evaluated as assessable or not and if not, the reason should be recorded:  
1 = Artifacts due to patient   
2 = Artifacts due to machine 
3 = Injection technical failure 
4 = Inadequate anatomic coverage  
5= Other, specify  
 
7.2.5 Number, size and location  of lesions (on- site and off -site read)  
The investigator and IBR  is to record the following:  
- Number of lesions on pre and paired images 
- For the [ADDRESS_729134] representative lesions, the following will be recorded for each lesion  separately:   
ï‚§ The largest diameter of the lesion  
ï‚§ The location of the lesion  
- In case that more than 3 lesions are present, the investigator/ IBR has to enter in 
the clinical/imaging  eCRF how many lesions are present  (total number)   
 
7.2.6 Diagnostic confidence (on-site and off- site read)  
The investigator/IBR  will record in the clinical/imaging eCRF his/her diagnosis and his/her confidence 
in diagnosis for each patient for each pre and paired images of each contrast agent according to the Table 4 . 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 38 / 79 
 
 
Table 4: imaging diagnosis 
Diagnosis  
Primary  
 
 
Tumors   
 
  
Secondary   Glial tumor, low grade (I/II) 
 Glial tumor, high grade (III/IV)  
 Glial tumor, tumor grade cannot be determined  
 Meningioma 
 Schwannoma 
 Pi[INVESTIGATOR_2117] a denomas 
Others, to be specified  
  
 Brain metastasis  
 Spi[INVESTIGATOR_555383], to be specif ied 
Vascular diseases  Stroke  
Vascular malformation  
Others, to be specif ied 
Others To be specif ied 
Diagnostic confidence will be evaluated to determine the level of certainty that the investigator/ IBR 
assign to a diagnosis. This is defined as the degree of confidence that the information on the images 
represents the true and complete clinical pi[INVESTIGATOR_510] a patient.  
The degree of confidence will be rated on a 5 point scale:  
1 = nil: very uncertain 
2 = poor: uncertain 
3 = moderate: moderately certain  
4 = high: good certainty  5 = excellent: very certain  
When the investigator/IBR  chooses â€˜not assessableâ€™ for diagnosis, by [CONTACT_555444] 
1 (= very uncertain).  
7.2.[ADDRESS_729135]- enhance d MRI on patient treatment plan  (on-site) 
The impact on patient  treatment plan will be assessed by [INVESTIGATOR_2394] -site radiologists and will be summarized 
for each contrast agent . At the end of visit 2 and at the end of visit 4, after having completed all the 
sequences of images required by [CONTACT_760] (images set  1b or set  2b), the investigator will have to 
document if the patient â€™s treatment plan could have been changed based on the images obtained 
(yes/no) and if yes, he/she would have to specify  the therapeutic management proposed based on 
radiological assessment:  
- Surgery  
- Biopsy 
- Chemotherapy 
- Radiotherapy 
- Other treatment: specify  
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 39 / [ADDRESS_729136] to Noise  Ratio (CNR), Percentage Enhancement (E%)  of lesion(s ), lesion 
to Background Ratio (LBR) (off- site) 
The 3 quantitative criteria (CNR, E% , LBR) will be  calculated by [CONTACT_4676], for each contrast agent, in 
averaging the parameter for maximum [ADDRESS_729137] to Noise ratio (CNR)  
ð¶ð‘ð‘… =  ð‘†ð¼ð‘™ð‘’ð‘ ð‘–ð‘œð‘›âˆ’ ð‘†ð¼â„Žð‘¡
ð‘†ð·ð‘›ð‘œð‘–ð‘ ð‘’ 
where  SIlesion  = Signal intensity of lesion . 
SIht = Signal intensity of healthy tissue (brain or spi[INVESTIGATOR_1831]) . 
SD noise = Standard D eviation (SD) of background noise. 
o Percentage enhancement  (E%) of lesion (s) 
ð¸% =  ð‘†ð¼ð‘ð‘œð‘ ð‘¡âˆ’ ð‘†ð¼ð‘ð‘Ÿð‘’
ð‘†ð¼ð‘ð‘Ÿð‘’x100  
where  SIpost = Signal intensity  of lesion  on post  injection image s. 
SIpre = Signal intensity  of lesion on pre injection images. 
o Lesion to Background Ratio (LBR)  (pre and post)   
LBR  =ð‘†ð¼ð‘™ð‘’ð‘ ð‘–ð‘œð‘›
ð‘†ð¼ð‘ 
where  SIlesion = Signal intensity of  lesion . 
SIb= Signal intensity of background (healthy tissue  in brain or spi[INVESTIGATOR_1831]). 
 
7.2.9 Overall diagnostic preference (off- site read).  
The evaluation will be performed in a global matched -pairs fashion (image s set 1b and 2b). For each 
randomized patient , all images ( paired image set 1b or 2b ) from the first MR examination, labeled as 
examination 1, will be displayed simultaneously with the corresponding paired images from the 
second MR examination, labeled as examination 2.  
The assessment will be performed on all pos t-contrast T1- weighted images with 3-point scales: 
o 1: when  examination 1 is preferred to examination 2  
o 0: when  no preference is observed  
o 2: when  examination [ADDRESS_729138] one or more of the following six reasons for this preference:  
â€¢ Contrast enhancement was superior  
â€¢ Delineation of normal structure was better  
â€¢ Delineation of at least one lesion was better  
â€¢ Internal structure of lesions was better visualized  
â€¢ More lesions were identified  
â€¢ Diagnostic confidence was greater (specify one or more reason(s): detection of 
lesions, characterization of disease, assignment of a grade to disease (i.e., high or 
low grade in the case of intraaxial gliomas), definition of extent of disease, or 
other reasons that had to be specified on the imaging eCRF)  
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 40 / 79 
 
 
7.2.10 Safety profile of gadopi[INVESTIGATOR_555337] (on -site).  
The safety assessments will be followed up by [CONTACT_555445], injection site tolerance, 
clinical laboratory parameters (blood s amples) and adverse events (AEs) reporting . 
o Vital signs  
Vital signs (supi[INVESTIGATOR_555384], pulse rate) will be measured and recorded 
according to the following schedules: 
ï‚§ Prior to each contrast agent injection (V2 is considered as baseline value)    
ï‚§ At 60  Â± [ADDRESS_729139] agent injection 
ï‚§ One day after each contrast injection  
Prior to the first injection , all clinically significant abnormal value might be reported in medical 
history section or AE section as  per investigatorâ€™ s judgement. After the first contrast agent injection, 
all clinically significant abnormal value , as per investigatorâ€™s judgement, will be recorded as AEs. 
o Injection -site tolerance  
For all patients, injection -site tolerance (pain, eruption, extravasation, inflammation, or other)  will be 
assessed over [ADDRESS_729140] injection (during the injection, 60 Â± [ADDRESS_729141] injection and the day after injection) and over a longer period if the investigator becomes aware of any related 
AE. In case of injection -site pain, the patient will be asked to specify the level of pain using a Numeric 
Pain intensity Scale (NPS ) from 0 (no pain) to 10 (maximal pain). 
o Local laboratory parameters  
Serum creatinine and eGFR will be obtained from local laboratory of each site prior MRI  and one day 
post IMP injection. The same local methods of serum creatinine dosage and eGFR calculation should 
be used throughout the trial for a same patient. 
According to ESUR guidelines: Post -contrast acute kidney injury (PC_AKI)  is defined as an increase 
i n  s e r u m  c r e a t i n i n e  o f  â‰¥  0 . 3  m g / d L or of â‰¥ 1.[ADDRESS_729142] agent.  
For this trial, it is up to investigator to evaluate any change in serum creatinine within trial period as 
clinically significant or not; the investigator  will report any clinically significant change as an AE .. 
o Clinical laboratory parameters  
For each patient, blood samples will be performed from visit 2 to visit 5.  The following parameters will be obtained and assessed  centrally :  
â€¢ Hematology: Red Blood Cells (RBCs), White Blood Cells (WBCs), neutrophils, eosinophils, basophils, lymphocytes and monocytes, platelet count, hemoglobin, hematocrit, Mean red blood Cells Volume (MCV). 
â€¢ Biochemistry: sodium, potassium, chloride, Blood Urea Nitrogen (BUN) / urea, total protein, calcium, phosphorus, total bilirubin (and indirect bilirubin), conjugated bilirubin, Aspartate 
Amino Transferase (AST), Alanine Amino Transferase (ALT), alkaline phosphatase, Lactate 
DeHydrogenase (LDH), Triglycerides, Cystatin C. 
The central laboratory will flag laboratory values falling outside of the normal ranges on the central 
laboratory report (which the investigator should review and sign off). 
Prior to the first injection , all clinically significant abnormal value  might be reported in medical 
history section or AE section as  per investigatorâ€™s judgement. After the first contrast agent injection, 
all clinically significant abnormal value , as per investigatorâ€™s judgement, will be recorded as AEs. 
o Adverse events  
Adverse Event s will  be recorded throughout patient participation (see section  9.1.2 ).  

 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 41 / 79 
 
 
8 TRIAL  SCHEDULE AND PROCEDURES  
The schedule of time and events to be performed is given in Table 1: Trial flow chart . 
 
8.1 Trial  Schedule  
8.1.1 Screening Visit â€“ Visit 1 â€“ Day (-7) to Day 0  
During this visit, the following tasks or assessments will be performed: 
â€¢ Written informed consent will be obtained from the patient  as described in Section 
13.3;  
â€¢ The patient  will be attributed an Identification Number (see section  4.3); 
â€¢ Checkin g of all eligibility criteria ; 
â€¢ Recording of demographic data (sex, race, ethnic data, height, age);  
â€¢ Documentation of relevant medical history/current medical condition present before 
signing the informed consent including CNS disease justifying the MRI ; 
â€¢ Recording of patient intolerance history related to contrast agent: if previous 
intolerance to contrast agent, the type of the product should be collected;  
â€¢ Documentation of previous CT/MRI or other imaging procedures documenting CNS lesion dated less than 12 months prior to ICF signature; 
â€¢ Documentation of presence/absence of brain metastasis ( in case of brain metastasis, 
the corresponding primary cancer will be recorded in medical history) ; 
â€¢ A routine physical examination (performed by a physician) including  the examination 
of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, 
heart, abdomen, back, lymph nodes, extremities, vascular and neurological; 
Information indicating the global assessment (normal or abnormal (specify)) of the 
physical examination should be recorded on source documentation; 
â€¢ Review and record ing of concomitant treatments;  
â€¢ A urine pregnancy test for all women of childbearing potential should be done and 
must be negative.  
â€¢ IWRS connection for recording the p atient  screening visit;  
â€¢ First trial MRI visit and examination needs to be scheduled within 7 days (or can be 
performed on the same day if all the inclusion/non -inclusion criteria are met).  
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 42 / 79 
 
 
8.1.2 Imaging/Randomization Visit â€“ 1st MRI â€“ Visit 2 â€“ Day 0  
During this visit, the following assessments  or tasks  will be performed:  
Procedures to be performed prior to MRI examination  
â€¢ Checking of all the eligibility criteria;  
â€¢ Any changes in concomitant treatments /procedures/therapeutic measures  since the last 
visit will be documented;  
â€¢ Measurement of vital signs  (systolic and diastolic blood pressure (BP) and pulse Rate 
(PR)) and  weight;  
â€¢ A urine pregnancy test will be performed for female patient of childbearing potential 
and must be negative  (test done at V1 will not be repeated at V2  if V1 done one day 
prior to V2. If V1 and V2 are done on the same day, one pregnancy test should be 
performed prior to patient randomization);  
â€¢ Blood sample collection for local dosage of serum creatinine and evaluation of eGFR (results should be available prior to patient randomization to check eligibility criteria. 
eGFR value should be â‰¥ 3 0 mL/min/1.[ADDRESS_729143] MRI);  The same local 
methods of serum creatinine dosage and eGFR calculation should be used throughout the trial for a same patient ; 
â€¢ Blood samples will be collected according to central laboratory manual;  
â€¢ Assessment of AEs will be documented  (see section 9 );  
â€¢ IWRS connection will be done to randomize the patient , to obtain the IMP box number , 
to calculate the volume of IMP to be administered based on the body weight and to 
record the date of the visit.  
Unenhanced and contrast -enhanced MRI examinations:  
â€¢ Unenhanced and contrast-enhanced MRI will be performed according to the required sequences specified in Section  8.2.2) . 
The appropriate dose/volume of gadopi[INVESTIGATOR_555385] a bolus at 
the recommended rate of 2 mL/second using a power injector or manual injection in a peripheral vein 
of the antecubital region (recommended). IMP injection will be followed by a saline flush injection.  
The following information will be documented in the source document and  reported on clinical eCRF 
pages:  date and time of contrast agent injection, location of injection site, actual volume administered 
(documentation of difference from theoretical volume), actual injection rate, overdose (if any), number of vials dispensed, number of IMP  injected, injection method (power injector or manual), injection of 
saline flush (yes/no) . 
The start time of contrast injection  will be recorded .  
Procedures to be followed after MRI examination:  
The patient will stay at the trial site for 60  Â± 15minutes  after the MRI examination is completed  and 
the following procedures will be performed:  
â€¢ Use/change  of concomitant treatment s during the visit will be documented ; 
â€¢ Vital signs (systolic and diastolic BP  and PR) will be obtained 60 Â± [ADDRESS_729144] agent.  
â€¢ Injection- site tolerance (pain, eruption, extravasation, inflammation, or other)
 will be  
assessed during the injection and 60  Â± [ADDRESS_729145] agent ; 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 43 / [ADDRESS_729146] to complete a Numeric Pain intensity Scale to 
indicate the pain intensity. Any sign of local intolerance will be reported as AE in the 
corresponding clinical eCRF page.  
â€¢ Assessment of AEs  will be documented ( see section 9 );  
â€¢ Evaluation of the potential impact of contra st-enhanced MRI on patient treatment plan;  
â€¢ Safety follow -up visit (Visit 3) needs to be scheduled [ADDRESS_729147] agent 
injection ; 
â€¢ Scheduling of the second MRI examination (visit 4) between [ADDRESS_729148] 
visit 2.  
8.1.3 Safety Visit â€“ Visit 3 â€“ [ADDRESS_729149] visit 2  
During this visit, the following assessments  or tasks  will be performed:  
â€¢ Use/change  of concomitant treatment s/procedures/therapeutic measures  will be 
documented;  
â€¢ Blood sample collection for local dosage of serum creatinine and evaluation of eGFR . 
The same local methods of serum creatinine dosage and eGFR calculation should be 
used throughout the trial for a same patient ; 
â€¢ Blood samples will be collected according to c entral laboratory manual;  
â€¢ Vital Signs (systolic and diastolic BP, PR) should be recorded;  
â€¢ Injection- site tolerance is to be evaluated ; In case of pain, the patient will have to 
complete a Numeric Pain intensity scale to indicate the pain intensity.  Any sign of local 
intolerance will be reported as AE in the corresponding clinical eCRF page.  
â€¢ Assessment of local serum creatinine results as per ESUR guidelines (see section 
7.2.10)  
â€¢ Assessment of AEs  will be documented ( see section 9 );  
â€¢ IWRS connection to record the trial visit;  
â€¢ Remind the date of visit 4 to the patient.  
8.1.4 Imaging Visit â€“ Visit 4 â€“ 2nd MRI â€“ [ADDRESS_729150] V2  
Procedures to be performed prior to MRI examination  
â€¢ Checking of non- inclusion criteria (see section 4.2);  
â€¢ Measurement of vital signs (systolic and diastolic BP and PR)  and weight;  
â€¢ Any changes in concomitant treatment s/procedures/therapeutic measures  since the last 
visit will be documented;  
â€¢ A urine pregnancy test for female patient of childbearing potential will be performed 
prior to the trial MRI  and must be negative; 
â€¢ Blood sample collection for serum creatinine dosage and verification that the local 
eGFR value is â‰¥ 3 0 mL/min/1.73 m2. The same local methods of serum creatinine 
dosage and eGFR calculation should be used throughout the trial for a same patient ; 
â€¢ Assessment of local serum creatinine results as per ESUR guidelines (see section 
7.2.10)  
â€¢ Blood samples will be collected according to c entral laboratory manual; 
â€¢ Assessment of AEs  will be documented ( see section 9 );;  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 44 / 79 
 
 
â€¢ IWRS connection will be done to obtain the IMPs box number , to calculate the volume 
of IMP to be administered based on the body weight and to record the date of the visit.  
Unenhanced and contrast- enhanced MRI examinations:  
â€¢ Unenhanced and contrast -enhanced MRI will be performed according to the required 
sequences specified in Section 8.2.2).  
The appropriate dose/volume of gadopi[INVESTIGATOR_555385] a bolus at 
the recommended rate of 2 mL/second using a power injector or manual injection in a peripheral vein 
of the antecubital region (recommended). IMP injection will be followed by a 0.9% saline flush 
injection . 
The following information will be documented in the source document and reported on clinical eCRF 
pages:  date and time of contrast agent injection, location of injection site, actual volume adminis tered 
(documentation of difference from theoretical volume), actual injection rate, overdose (if any), number 
of vials dispensed, number of IMP injected, injection method (power injector or manual), injection of 
saline flush (yes/no).  
The start time of contrast injection will be recorded.  
Procedures to be followed after MRI examination:  
The patient will stay at the trial site for 60  Â± 15min after the MRI examination is completed and the 
following procedures will be performed:  
â€¢ Use/change of concomitant treatments during the visit will be documented;  
â€¢ Vital signs (systolic and diastolic BP and PR) will be obtained 60 Â± [ADDRESS_729151] agent.  
â€¢ Injection- site tolerance (pain, eruption, extravasation, infla mmation, or other) will  be 
assessed during the injection and 60  Â± [ADDRESS_729152] agent; 
In case of pain, the patient will have to complete a Numeric Pain intensity Scale to indicate the pain intensity. Any sign of local intolera nce will be reported as AE in the 
corresponding clinical eCRF page.  
â€¢ Assessment of AEs will be documented  (see section 9 ). 
â€¢ Evaluation of the potential impact of contrast -enhanced MRI on patient treatment plan;  
â€¢ Safety follow -up visit (Visit 5 ) needs to be scheduled [ADDRESS_729153] agent 
injection;  
8.1.5 Safety Vis it â€“ Visit 5  â€“ [ADDRESS_729154] Visit 4  
During this visit, the following assessments  or tasks  will be performed:  
â€¢ Use/change  of concomitant treatment s/procedures/therapeutic measures  will be 
documented;  
â€¢ Blood sample collection for local dosage of serum creatinine and evaluation of eGFR . 
The same local methods of serum creatinine dosage and eGFR calculation should be used throughout the trial for a same patient
; 
â€¢ Assessment of local serum creatinine results as per ESUR guidelines (see section 7.2.9)  
â€¢ Blood samples will be collected according to c entral laboratory manual;  
â€¢ Vital Signs (systolic and diastolic BP, PR) should be recorded;  
â€¢ Injection- site tolerance is to be evaluated ; In case of pain, the patient will have to 
complete a Numeric pain intensity scale to indicate the pain intensity.  Any sign of local 
intolerance will be reported as AE in the corresponding clinical eCRF page.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 45 / 79 
 
 
â€¢ Assessment of AEs  will be documented (any AE not recovered should be followed up 
(see section  9.1.2);   
â€¢ IWRS connection to record the trial visit;  
During the course of the trial, if a patient is screen failed or is prematurely discontinued  (see section  
14.3.2), the new patient status should be recorded in the IWRS and in the clin ical eCRF.  
 
8.[ADDRESS_729155] be recorded in the clinical eCRF : the manufacturer  and field strength of the MRI 
device.  
For a single patient, the same MR equipment for the two MRI examinations should be used. 
 
8.2.[ADDRESS_729156]- enhanced images in each patient .  
The required sequences and parameters for gadopi[INVESTIGATOR_555386]:  
For brain (axial orientation and whole brain are required):  
ïƒ˜ Unenhanced : 
â€¢ 2D T1 -weighted SE/TSE images  
â€¢ 3D T1 -weighted GRE images  
â€¢ 2D T2 -FLAIR  
â€¢ T2-weighted T SE images  
ïƒ˜ Contrast-enhanced: 
â€¢ 2D T1 -weighted SE/TSE images  
â€¢ 3D T1 -weighted GRE images  
For spi[INVESTIGATOR_050]:  
ïƒ˜ Unenhanced : 
â€¢ T2-weighted T SE images ( sagittal)  
â€¢ T1-weighted SE/TSE images ( sagittal)  
ïƒ˜ Contrast-enhanced : 
â€¢ T1-weighted SE/TSE (axial)  
â€¢ T1-weighted SE/TSE ( sagittal)  
 
It is not allowed to add any sequence, other than the one described above, between contrast agent 
injection and axial 3D T1-weighted GRE  for brain and sagittal T1-weighted SE/TSE for spi[INVESTIGATOR_050].  
Sequence parameters for brain and spi[INVESTIGATOR_555387] I maging Manual. 
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 46 / [ADDRESS_729157] with patient s, 
investigators, or other individuals involved in the trial. 
Images will be evaluated by [CONTACT_555421] a centralized manner. All 
images will be sent to a core laboratory, which will p repare the images for evaluation. The file headers 
of all the images transmitted in DICOM format are to be edited to remove patient or site identification. 
For all images, any sequence information will be removed. A complete audit trail of any changes to 
the file headers will be maintained.  
The blinded image evaluations will be performed by [CONTACT_555446] ( [ADDRESS_729158] will perform lesion tracking ). An 
imaging eCRF will be used to ensure that the images and the diagnostic findings are properly aligned 
and to ensure that all data necessary for the trial purpose are documented by [CONTACT_555447].  
 
8.4.1 Manuals and Supplies  
Guerbet (or its Imaging Core Laboratory) will document the imaging tasks and obligations of the 
investigational site in an Imaging Manual. As defined in Section 8.2.2, the standardized image 
acquisition guidelines or imaging protocol will be provided to the sites as part of the Imaging Manual.  
In addition, the Imaging Manual will de tail the steps required for masking confidential patient 
information and transferring images to the Imaging Core Laboratory .  
Guerbet (or the Imaging Core Laboratory) will document the central imaging process in a Blinded  
Imaging Evaluation Charter . 
 
8.4.2 Site Qualification  
Guerbetâ€™s agent (CRO, Imaging Core Laboratory or monitors) will perform pre -trial site selection. 
This contact [CONTACT_555448], is 
programmed and prepared prior to enrolment of the first patient and that the Imaging Manual will be accurately followed by [CONTACT_093].  
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 47 / 79 
 
 
8.4.3 Receipt and Tracking of Images  
Guerbet (or its Imaging Core Laboratory) will request that investigational sites s ubmit anonymous 
images to the Imaging Core Laboratory in a format that will be agreed prior to trial start. Images  will 
be tracked in the database of the Imaging Core Laboratory . 
 
8.4.[ADDRESS_729159] been followed. In the event that a problem with an image is identified (e.g.: inappropriate anatomical coverage, 
inconsistency of images parameters with the imaging protocol, poor quality images), the 
investigational site will be notified concerning the nature of the problems and the steps required for corrective action. The Imaging Core Laboratory will follow -up on all cases requiring remedial action 
by [CONTACT_41166]. Guerbet (or the Imaging Core Laboratory) may conduct site training for investigator sites with recurring image quality issues. 
 
8.4.[ADDRESS_729160] to successfully complete training sessions (refer to â€œ Blinded Image 
Evaluation C harter â€ for details).  
Independent readers are readers that are completely unaware of findings of other readers (including findings of other blinded readers and on- site investigators) and are readers who are not otherwise 
influenced by [CONTACT_555449].  
The term â€œindependentâ€ means that the readers involved in centralized review do not participate in 
image acquisition and images are read outside the image acquisition site.  
 
8.4.6 Image Randomization  
When a sufficient number of images are available for  readings, a batch of images will be presented to 
the blinded readers.  
The patients within each batch will be ordered at random without stratification into groups of patients.  
Various modalities of images from the same patient will not be presented in the  same batch and the 
Imaging Core Laboratory will ensure an appropriate wash -out period between the evaluations of 
images from two modalities (Pre & Paired images) and between two MR examinations for the same 
patient, to minimize recall bias.  
 
8.4.7 Blinded Asses sment of Images  
Imaging database including all evaluable images will be assessed by [CONTACT_389259]. The 
reading will be performed in a strictly fully blinded manner. 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 48 / 79 
 
 
No communication on patient  specific image findings will be allowed between the i ndependent 
readers once the blinded reviews begin. 
To ensure that the centralized reading evaluations remain independent, each individual reader 
evaluation will be locked as they occur (i.e., it will not be possible to alter the evaluation). 
 
8.4.8 Inter & Intra -reader Variability Assessment  
The assessments of inter - and intra- reader variability will be done in the final analysis.  
Inter -reader variability will be evaluated on the whole set of trial patients since each patient will be 
read by [CONTACT_555450].  
Intra -reader variability: individual readers will perform repeat image evaluations of 10 % of cases 
randomly determined. The cases used for intra -reader variability assessment will be re-introduced 
randomly and re- read during the course of the reading. To minimize recall bias, intra -reader variability 
will be assessed approximately after the first [ADDRESS_729161] evaluation of a given image set will be included in the efficacy 
analysis.  
 
8.4.9 Lesion tracking/ Matching  
A concordance reading process (lesion tracking) will be performed as an independent off -site 
procedure. The purpose is to guarantee an unambiguous assignment (matching) of the lesions between 
modalities (Pre and Paired images)  of the same MR examination  between two MR examinations for 
the same patient,  and between readers. Lesion tracking will be carried out by [CONTACT_555451] (so- called concordance reader) in blinding condition (except the ID number of lesions) on 
the basis of the off -site readersâ€™ assessments. Once the concordance process is done, 
correspondence/tracking lesion tables should be obtained, so that lesions could be compared for analysis within readers or for the inter - and intra- reader (refer to trial â€œBlinded Image Evaluation  
Charterâ€ for details).  
 
8.4.10 Image Archive and Final Deliverables  
All imaging data will be maintained in a secure environment. The Imaging Core Laboratory will maintain a centralized image archive that will contain every imaging examination received from the clinical investigators for the trial . Measurements will also be stored so that these data may be audited 
if necessary. A copy of images transferred by [CONTACT_555452]. 
 
8.5  Non Imaging Central procedures : central laboratory 
A central laboratory will be used for all scheduled laboratory tests in this trial except for the pregnancy 
test and creatinine and eGFR  which will be assessed locally. The investigator will be provided with a 
list of normal ranges prior to the start of the trial . The central laboratory will provide the necessary kits 
to collect the blood samples and will also provide appropriate information regarding shippi[INVESTIGATOR_555388] .  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 49 / 79 
 
 
The following parameters will be obtained and assessed:  
â€¢ Hematology: Red Blood C ells (RBCs), White Blood C ells (WBCs), neutrophils, 
eosinophils, basophils, lymphocytes and monocytes, platelet count, hemoglobin, 
hematocrit, M ean red blood C ells Volume (MCV). 
â€¢ Biochemistry: sodium, potassium, chloride, Blood U rea Nitrogen (BUN) /  urea, total 
protein, calcium, phosphorus, total bilirubin  (and indirect bilirubin), conjugated 
bilirubin, A spartate Amino T ransferase (AST), Alanine Amino T ransferase (ALT), 
alkaline phosphatase, L actate DeH ydrogenase (LDH), Triglycerides, Cystatin C . 
All laboratory reports must be promptly reviewed by [CONTACT_555453]. Change(s) in post- dose test values considered clinically significant, which would require either 
additional control or therapy, must be documented in the patientâ€™s source document. All post -injection 
values considered clinically significant  by [CONTACT_555454] (sequelae) . 
Central laboratory results obtained at V2 prior to IMP injection should be assessed by [CONTACT_555455] A E section as per investigator 
judgement. 
Samples obtained in this trial will not be retained or used for any other purposes.  
Name [CONTACT_555503]. 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 50 / [ADDRESS_729162], serious or not, that occurred in a trial patient  during its participation to the trial 
according to the below instructions . Special situations such as medication errors, misuses, suspi[INVESTIGATOR_555389], unusual failure in efficacy, overdose (symptomatic or 
not), drug exposure during pregnancy or breastfe eding even if uneventful, suspected drug -drug 
interaction with another product (symptomatic or not)  will also be reported to Guerbet.   
The definition, modalities of collection and reporting are provided below. 
 
9.1 Adverse Event  
9.1.1 Definition of Adverse Event  
An Adverse Event (AE) is any untoward medical occurrence in a patient  or clinical investigation 
patient  administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment.  
An AE can therefore be:  
- any unfavorable and unintended sign, including an abnormal finding from an additional 
examination (lab tests, X -ray, ECGâ€¦) deemed clinically significant by [CONTACT_093];  
- any symptom or intercurrent disease;  
- any worsening during the trial of a symptom or a disease already present when the patient 
entered the trial (increase in frequency and/or intensity ). 
(Note: for US participating sites only: for Guerbet sponsored clinical studies, the term adverse events 
will be used (as opposed to adverse drug experience )). 
Any disease identified and diagnosed by [CONTACT_555456] . It may  be collected in clinical e CRF as medical history or trial  disease.   
The patient â€™s disease under investigation and part of inclusion criteria or any pre -existing disease is 
not reported as AE, nevertheless, any worsening of such pathologies  during the course of the trial has 
to be considered as an AE. 
 
9.1.2 Collection and recording of Adverse Events  
The Investigator or his/her designee will invite the patient  to report any experienced abnormality as 
part of the usual clinical follow -up. In addition, any abnormal finding  assessed as cl inically significant 
in the context of the trial  by [CONTACT_737] (see section 9.1.1 ) should be considered as AE  and 
reported in the AE section of the clinical e CRF . 
All AEs, whether considered as related or not to the IMP  and/or any protocol procedure s including 
imaging procedures, and whether serious or not, should be reported and documented in the medical 
file and the appropriate section of the clinical e CRF  according to the Table 5 .  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 51 / 79 
 
 
Table 5: Collection and reporting of AEs throughout and after the trial 
Periods  and types of AEs to be 
reported  Screening  From 
randomization to 
last follow -up visit  After end of 
participation 
Not related non- serious  AEs  X* X  
Not related SAEs  X X  
Adverse Event of Special Interest 
(AESI)  X X  
Related$ AEs (serious or not)  X X X 
Pregnancy cases  NA X X** 
$ related to the IMP  and/or any protocol procedures including imaging procedures  
* The events w hich occur before the first IMP administration, and which are not serious and not related to the 
trial procedures, might be recorded as medical history upon the investigatorâ€™s judgement.  
** see the period of collection described in section 9.3.2  
 
As reminder the  patientâ€™ s participation is defined as the period from the screening visit (ICF signature) 
to the last trial visit in the general case and defined in section [ADDRESS_729163] provide a justification in the medical file and eCRF . 
 
9.1.3 Description of Adverse Events  
The following guidelines and definitions should be used by [CONTACT_555457] e CRF and  any specific AE  report forms : 
â€¢ Nature (diagnosis) of AE:  preferably an overall diagnosis or syndrome, rather than individual 
symptoms or signs. The investigator must report AE using standard medical terminology. The same terms should be used in the source documentation and in the  clinical e CRF.  
â€¢ Date and time of onset:  date and clock time of the AE start . 
â€¢ Intensity:  
o Mild: the patient  is aware of the sign or symptom, but it does not interfere with her/his 
usual daily activities and/or it is of no clinical consequence  
o Moderate:  the AE interferes with the usual daily activities of the patient  or it is of 
some clinical consequence  
o Severe:  the patient is unable to work normally or to carry out his/her usual daily 
activities, and/or AE is of definite clinical consequence.  
â€¢ Date of th e event end  (or consolidation) : This date is the date when the event has come to its 
ends or to its initial intensity (for the events that had been an aggravation of a pre-existing disorder) . If the AE is still ongoing by [CONTACT_555458] -up for the patient (i.e. 
last trial visit), the patient  should be followed- up until AE resolution or a justification should 
be provided by [CONTACT_737] (i.e. chronic disease) in the medical file.  
â€¢ Causal relationship to the IMP : 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 52 / 79 
 
 
o Related: the definition of adverse reaction  (AR)  implies a reasonable possibility of a 
causal relationship between the event and the IMP. This means that there are facts 
(evidence) or arguments to suggest a causal relationship.  
o Not related: A pplicable when no IMP has been administered (pre -administration 
period) or when no causal relationship exists between the trial drug and the event, but 
an obvious alternative cause exists (e.g. the patient â€™s underlying medical condition or 
concomitant therapy). 
â€¢ Causal relationship to a trial procedure  (blood test, imaging procedure itself etcâ€¦) : 
o Related : the definition of adverse reaction implies a reasonable possibility of a causal 
relationship between the event and the procedure. This means that there are facts 
(evidence) or arguments to suggest a causal relationship.  
 
o Not related : Applicable when no procedure was performed yet or when no causal 
relationship exists between the trial  procedure and the event, but an obvious 
alternative cause exists (e.g. the patient â€™s underlying medical condition or 
concomitant therapy). 
â€¢ Outcome:  
o Recovered /resolved : the AE is no longer present at any intensity  or return to baseline 
intensity (for pre -existing disorders) or values for biological data . 
o Recovered/resolved with sequelae: the AE is resolved but residual effects are still 
present (to be specified on the AE form). 
o Not recovered /not r esolved : the AE is still present at the last contact [CONTACT_10970] . 
o Fatal: this AE caused or directly contributed to the patient â€™s death . 
â€¢ Action taken w ith re gard to administration of the IMP: 
o No action : for AE occurring during the pre-treatment/procedure after the post -
treatment/procedure period, or if the IMP dosing/administration would not change in 
spi[INVESTIGATOR_555390] .  
o IMP interrupted: the IMP administration is interrupted (e. g. extravasationâ€¦) or the patient  is withdrawn from any other IMP administration planned during the trial but 
without known contra-indication to the drug. 
o IMP definitively discontinued: the event leads to a definite contra- indication to the 
drug (e.g. confirmed hypersensitivityâ€¦).  
o IMP unblinding.  
â€¢ Other action taken:   
o AE-targeted medication: the patient  took a medication (either prescription or non-
prescription) specifically for this AE. The drug(s) should be reported in the appropriate section of the clinical  eCRF (â€œconcomitant medication â€ section) . 
o Other AE -targeted action: therapeutic measures  other th an corrective drug 
administration (e.g. ice, heating pad, brace, castâ€¦) or  patient  underwent a procedure 
(surgery, physiotherapy, additional laboratory testâ€¦) for this AE. The therapeutic 
measure(s) should be reported in the appropriate section of the clinical e CRF 
(â€œprocedures/therapeutic measuresâ€ section) . 
o Trial  discontinuation: the AE leads to patient  discontinuation from the trial .  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 53 / 79 
 
 
â€¢ Adverse event of special interest (AESI) should be indicated (see section 9.3.3  for AESI 
definition ) 
â€¢ Assessment of the seriousness of the AE : see S ection 9.2 for SAE definition. 
 
9.2 Serious Adverse Event  
9.2.1 Definition of Serious Adverse Event  
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose (ICH E2A) :  
- Results in death  
- Is life -threatening  
- Requires in patient  hospi[INVESTIGATOR_1081] 
- Results in persistent or significant disability / incapacity  
- Is a congenital anomaly / birth defect  
- Is an i mportant medical event 
â€¢ Important medical event : medical and scientific judgement should be exercised in deciding whether 
expedited reporting is appropriate in situations  such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_555391]. These 
should also usually be considered serious.  
Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059] ; or 
development of drug dependency or drug abuse.  
â€¢ Life-threatening in the definition of a serious adverse event refers to an event in which the patient 
was at risk of death at  the time of  the event; it does not refer to an event which hypothetically might 
have caused death if it were more severe.   
â€¢ Hospi[INVESTIGATOR_555392]. 
Emergency room visits that do not result in admission to the hospi[INVESTIGATOR_555393]. 
In case of a SAE, the investigator is responsible for the measures to be taken to ensure the safety of the trial patients. 
Severe / Serious:  the term â€œsevereâ€ is used to describe the intensity (severity) of a specific event 
(within the scale mild, moderate, severe). This is not the same as â€œseriousâ€, which is based on patient event outcome or action criteria. The event itself may  be severe but  of relatively minor medical 
significance.  
In this protocol, the following situations will not be considered as SAE, providing that they are clearly 
documented as such in the patient â€™s source data:  
- Any hospi[INVESTIGATOR_555394], provided there is no aggravation of the disease to which it is related.  
- Hospi[INVESTIGATOR_602], which are not associated to an adverse event (su ch as hospi[INVESTIGATOR_555395] -up).  
No anticipated SAE is defined in this protocol as patient population under trial is suffering from CNS 
lesion s but not from a specific pathology therefore no anticipated SAE has been identified . 
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 54 / 79 
 
 
9.2.2  Reporting Serious Adverse Events  (SAE)  
All SAEs  must be reported immediately  by [CONTACT_555459] . Therefore, t he investigator 
must immediately  forward to Guerbet P harmacovigilance department a duly completed report form for 
SAE , AESI  or pregnancy  provided by [CONTACT_555460] , even if it is obvious 
that more data will be needed in order to draw any conclusion:  
- By e-mail to: pharmacovigi lance.headquarters@guerbet .com   
- Or Fax #: + 33 (0)1 45 91 67 70 
In case of emergency, Guerbet Pharmacovigilance department may be contact[CONTACT_6811] :  
+ 33 (0)1 45 91 50 00. 
SAEs, occurring at any time during the patientâ€™s participation to the trial have to be reported also in 
medical file and  in the appropriate section of the clinical e CRF ( see Section  9.1.2 ) 
In order to allow the assessment and eventual subsequent regulatory reporting of the case, the 
following minimum information should be fille d in:  
- Patient â€™s details including age, sex and patient â€™s trial  identification number,  
- Patient â€™s medical history relevant to the assessment of the event , 
- Type of event by [CONTACT_34055] a diagnosis or if not available, symptoms,  
- Date and time of onset of the event ,  
- End date of the event (will be reported in a follow -up report if the event is still ongoing at the 
time of initial  notification) , 
- Date and time of investigational drug administration,  
- Seriousness criterion , 
- Causal relationship to the  investigational drug or procedure (mandatory), 
- Outcome at the time of reporting . 
If the investigator is aware of any new relevant information concerning a SAE (e.g.: outcome or any 
information that can have an impact on the assessment of the seriousness or the causal relationship 
between the SAE and the IMP), he has to send immediately to Guerbet Pharmacovigilance department  
the report form for SAE , AESI or pregnancy duly completed . 
In order to comply with current regulations as well as for compr ehensive assessment purposes, 
additional information (e.g. autopsy results, biological valuesâ€¦) or clarifications may be required by 
[CONTACT_555461] a timely fashion to ensure accurate follow -up and assessment of each case and should be 
transmitted, anonymized, with a specific form  as soon as they are available.  
SAEs should be followed up by [CONTACT_555462], if not 
possible, until stabilization of sequelae.  
SAEs associated with trial procedures are to be notified using the same reporting procedure as 
described above.  
According to local requirements, Guerbet or its representatives will communicate relevant safety information to the appropriate A gency(ies), IEC and/or all active investi gators, as it becomes 
available.  
The transmission of the information to Guerbet does not release the investigator from his 
responsibility to inform the regulatory authorities and or IEC/IRB , if applicable.  
No anticipated SAE has been identified in this trial therefore no modalities of collection and reporting are described.  

 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 56 / [ADDRESS_729164] (AESI ), serious or non-serious, is one of scientific and medical 
concern specific to the sponsorâ€™s product or programme, for which ongoing monitoring and rapid 
communication by [CONTACT_35348]. Such an event might warrant 
further inves tigation in order to characteriz e and understand it. 
For Guerbet , the transmission of an AESI to  the Guerbet Pharmacovigilance Department respects  the 
same time frame as an SAE  and should be reported using the report form for SAE, AESI or pregnancy 
. 
The AESI for this protocol is the following: Nephrogenic Systemic Fibrosis (NSF). 
 
9.3.4 Any suspi[INVESTIGATOR_555396].  
 
9.4 Other important safety issue /  new fact  
Any new data which may lead to a reassessment of the benefits / risks balance of the research or 
product being studied, changes in the use of that product, the conduct of the research or documents 
relating to the trial or to suspend or interrupt or modify the protocol of the trial  or similar searches 
have to be evaluated by [CONTACT_555429] . 
It may include any new event likely to affect the safety of the patient â€™s and that may be related to the 
conduct of the trial  or the development of the trial drug such as: 
ï‚§ A SAE  which could lead to the modification of the conduct of the trial  (ex: SAE 
associated with the trial procedures, S[LOCATION_003]R ). 
ï‚§ A new major finding from an animal study, 
ï‚§ A temporary halt of a trial for safety reasons if the trial  is conducted with the same IMP in 
another country by [CONTACT_555463], 
ï‚§ Recommendations of the safety committee  if any, where relevant for the safety of patient s, 
ï‚§ Increase in the frequency of an expected event considered as clinically significant.  
According to local requirements, Guerb et or its representatives will communicate relevant safety 
information to the appropriate Agency ( ies), IEC/IRB and/or all active investigators, as it becomes 
available.  
Consequently, this type of important safety issue might lead also to :  
ï‚§ Urgent safety measures and their notification  
ï‚§ Substantial trial documents modification s 
ï‚§ Premature discontinuation of the trial   
ï‚§ Premature discontinuation of the patient 
The Reference Safety Information (RSI) used for the assessment of expectedness of serious 
adverse reactions  is the investigator brochure in force for gadopi[INVESTIGATOR_555397].  
 

 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 57 / 79 
 
 
9.5 Unblinding Procedures  
The investigator may, under exceptional circumstances unblind the individual trial treatmen t group if 
he/she considers that this procedure is relevant to the safety of the trial  patient . Individual trial 
treatment unblinding is described in Section 5.3.3. Information that unblinding has been performed by 
[CONTACT_555464] , in the clinical eCRF and  in the report 
form for SAE , AESI or pregnancy sent to Guerbet Pharmacovigilance Department , if applicable. 
Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]Rs) will be unblinded by [CONTACT_555465]; however, these S[LOCATION_003]Rs will 
remain blinded to the investigator and to Guerbet blinded personnel r esponsible for trial management, 
data analysis, and interpretation of results at the trialâ€™s  conclusion.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 58 / 79 
 
 
10 SCREEN FAILURE AND PREMATURE DISCONTINUATION  
10.1 Screen failure 
Screen fail ed patients are defined as patient s who consent to participate in the clinical trial but are not 
subsequently  randomized. For this trial, a patient who has signed ICF cannot be re -screened.  
Data  collected for screen failure patient s, refer to section 14.3.2. 
 
10.2 Premature Discontinuation of the  trial per Guerbet  Decision  
Guerbet reserves the right to discontinue the trial  at any time for medical, administrative or other 
reasons.  
Guerbet w ill inform the relevant authorities in each country, the ethics committees, the trial  site 
investigators, pharmacists and hospi[INVESTIGATOR_555398].  
 
10.3 Premature discontinuation  
Premature discontinued patients  are defined as patients  who consent to participate in the clinical trial 
and are discontinued from the trial after randomization 
Data collected for premature discontinued patients: Please refer to section 14.3.2. 
 
10.4 Reasons for patient â€™s screening failure and premature discontinuation  
Criteria for screen failure and premature discontinuation of patients : 
- Inclusion criteria not met /Non- inclusio n criteria met  
- Adverse Event (according to the investigatorâ€™s judgement) ; 
- Adverse Event of Special Interest (AESI);  
- Withdrawal of patient â€™s consent :  
o If the patient withdraws consent for disclosure of future information, Guerbet  may retain 
and continue to use any data collected before such a withdrawal of consent. 
o If a patient  withdraws from the trial, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site â€™s records . 
- Patient  lost to follow -up (date of last contact [CONTACT_555466]). Any effort will be undertaken to know the reason for this loss to follow -up and/or 
to exclude any adverse reaction as this reason. This will be documented in the patient â€™s medical 
file; 
- Discovery of an unexpected, significant, or unacceptable risk to a patient enrolled in the trial ; 
- At the discretion of the investigator if the patient  safety or well -being is not compatible with trial 
continuation; 
- Other reason (to be specified)  
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 59 / 79 
 
 
10.5 Enrolment  of additional patient  
Patient s prematurely discontinuing the trial will not be replaced.  
In the event of premature discontinuation, patients  will receive adequate follow- up from on- site 
investigators.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 60 / 79 
 
 
11 STATISTICAL CONSIDERATIONS  
The following sections summarize the statistical considerations , which are fully described in the 
Statistical Analysis Plan.  
11.1  Statistical Method  
Primary objective 1 :  superiority of Paired images versus Pre images of gadopi[INVESTIGATOR_555399]- primary criteria  
The null hypothesis is that the difference in mean scores between Paired images and Pre images for 
each of the [ADDRESS_729165] is performed at a one- sided 2.5% significance level for each co -primary criteria.  
All co -primary criteria are considered as following a standard normal distribution. Normality will be 
checked by [CONTACT_555467].  
To conclude that gadopi[INVESTIGATOR_555334]- enhanced MRI is superior to unenhanced MRI , the null hypothesis has 
to be  rejected for all co -criteria  simultaneously hence the overall T ype I error rate does not need  to be 
adjusted. 
 
Primary objective 2: non-inferiority of gadopi[INVESTIGATOR_555400] -primary criteria  
The null hypothesis is that the difference in mean scores between gadopi[INVESTIGATOR_555401] 3 primary criteria is equal to the non- inferiority margin .  
The alternative hypothesis is that the difference in mean scores between gadopi[INVESTIGATOR_555402] 3 primary criteria is greater than the non -inferiori ty margin . 
Studentâ€™s t -based two -sided 95% confidence interval (95%CI) of the gadopi[INVESTIGATOR_555334]-gadobutrol 
difference will be calculated for each co -primary criteria and compared to the non -inferiority margin.  
All co -primary criteria are considered as following  a standard normal distribution. Normality will be 
checked by [CONTACT_555467].  
To conclude that gadopi[INVESTIGATOR_555403] , the null hypothesis has to be rejected 
for all co -criteria simultaneously hence the overall Type I error rate does not need to be adjusted.  
Further, after the non- inferiority is demonstrated, the superiority of gadopi[INVESTIGATOR_555404]. No adjustment for multiplicity is needed as it is a simple closed 
testing procedure.  
For FDA,  the primary objective 1 is to be achieved.  
For EMA, both primary objectives 1 and 2 are to be achieved   
 
11.2 Sample Size  
Number of patients for the primary objective  1: 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 61 / 79 
 
 
Expecting that for each co -primary criteria, the difference in mean scores will be 0. 35 ([â€œPairedâ€ â€“ 
â€œPreâ€] within patient mean of lesion scores) with 1.[ADDRESS_729166] 90 % power when using a single group superiority t -test with a 0.025 
one-sided significance level.  
As a 2 0% drop -out rate is expected, sample size increases to 250 patients with CNS lesions . 
The success hypothesis used in the sample calculation (â€œPairedâ€ lesion score mean  is at least 0. 35 
higher than â€œPreâ€ lesion score mean ) is based upon the Gutierrez public ation [10] where the  minimal  
observed difference mean was 0.41 with a SD ranging from 0.5 to 0.8. 
Mean (SD) of the difference between combined unenhanced and gadobutrol-enhanced imaging vs 
unenhanced imaging (N = 336).  
Reader  Border delineation Internal 
Morphology  Degree of Contrast 
Enhancement  
1 0.67 (0.66) 0.62 (0.47) 1.26 (0.61) 
2 0.72 (0.78) 0.82 (0.61) 1.59 (0.77) 
3 0.43 (0.50) 0.41 (0.52) 1.06 (0.51) 
 
Considering that in the current trial the scale used is not exactly the same (4 -point scale instead of 3-
point scale for one parameter) and to account a possible greater heterogeneity, the difference is set to 0.[ADDRESS_729167] deviation. 
 
Number of patients for the primary objective 2 : 
- Non-inferiority margin:  
For EMA, both primary objectives [ADDRESS_729168] 
demonstration of the superiority of gadopi[INVESTIGATOR_555405] (objective 1). So, it 
can be considered as three -armed trial design with u nenhanced images as placebo as described in EMA 
guideline on the choice of the non- inferiority margin  [11]. As such, it is not necessary to define a 
value for non- inferiority margin to establish that gadopi[INVESTIGATOR_555406]. 
A 10% non- inferiority margin was considered clinically as an unimportant difference and therefore 
relevant to establish acceptable efficacy relative to gadobutrol (objective 2). Based on the Guerbet Phase IIb GDX -44-004 clinical trial results of lesion visualization criteria, the mean score for each of  
the 3 co-criteria is expected to be equal to 3.5, so the margin is set to 0.35 (10%). 
  
- Sample size hypothesis: 
The standard deviation on lesion visualization criteria for gadopi[INVESTIGATOR_555407] -44-004 clinical trial results  on lesion visualization criteria presented in the 
table below. 
 
Mean (SD) of the combined unenhanced and gadopi[INVESTIGATOR_555334]-enhanced imaging (N = 61). 
 
Reader  Border delineation Internal 
Morphology  Degree of Contrast 
Enhancement  
1 3.37 (0.55) 3.34 (0.64) 3.23 (0.80) 
2 1.97 (0.74) 1.71 (0.75) 3.76 (0.58) 
3 3.72 (0.49) 3.72 (0.49) 3.68 (0.50) 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 62 / 79 
 
 
 
Considering that the results for gado butrol would be similar  (meaning that the standard deviation of 
the difference is expected ranging from âˆš2*0.50=0.7 to âˆš2*0.80=1.15) and taking into account a 
possible greater heterogeneity  of patient population to be included in the trial , the expected standard 
deviation of difference between gadopi[INVESTIGATOR_555408] 1.75.  
  
For this 2x2 cross -over design, the statistical analysis is based on the observed Studentâ€™s t -based two -
sided 95% confidence interval (95%CI) of the  gadopi[INVESTIGATOR_555334]- gadobutrol difference for each co- primary 
criteria. An enrollment of 200  patients is deemed necessary for the lower limit of the 95% CI to exceed 
the non- inferiority margin set to 0. 35. Assuming 80% power and for each co- primary criteria, the  
expected difference in mean scores is [ADDRESS_729169] deviation of 1.75. If one assumed a patient drop- out rate of 20%, a minimum enrollment of 250  patients with CNS 
lesions is planned.  
Therefore, a total number of 250 patients will allow a s ufficient power to meet both primary 
objectives . 
 
11.3 Planned Analysis   
11.3.1 Disposition of patients  
Number of patients undergoing each visit will be presented by [CONTACT_555468] (gadopi[INVESTIGATOR_555334] -gadobutrol / 
gadobutrol- gadopi[INVESTIGATOR_555334]) and overall.  
The overall disposition will be presented by [CONTACT_555469]. The reason of screen failure will be 
presented overall and the reason of premature discontinuation will be presented by [CONTACT_555469]. 
(see section 10 for screen failure and premature discontinuation definition). 
Number of patients by [CONTACT_555470].  
 
11.3.2 Data Sets  Analyzed  
The patient sets for this trial are defined below :  
o The Screened patients Set (SPS) will include all patients having signed the inform consent 
form  
o The Safety Set (SS) will include all patients having received at least one injection of IMP 
regardless of the quantity  
o The Full Analysis Set 1 (FAS1) will include all patients who have a valid primary criterion 
assessment  
- FAS1 will include all patients who have both gadopi[INVESTIGATOR_555409] (for primary objective 1 ) 
- FAS2 will include all patients who have both gadopi[INVESTIGATOR_555410] (for primary objective 2)  
o The Per -Protocol Set (PPS): will include all patients who have no major protocol deviations 
and a valid primary criterion assessment.  
- PPS1 will include all patients from the FAS1 who have no major protocol deviations 
for primary criteria  [ADDRESS_729170] no major protocol deviations 
for primary criteria  2  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 63 / 79 
 
 
11.3.3 Protocol Deviations  
As per International Conference on Harmonization (ICH) E3 guideline, a protocol deviation is any 
change, divergence or departure from the trial  design or procedures defined in the protocol, with or 
without impact to the patient safety or the efficacy assessments.  
Protocol deviations will be gathered from monitoring files, clinical database and external vendors of 
off-site data (imaging, laboratory dataâ€¦).  
Protocol deviations will be split in major and non-major  deviations. A major deviation is defined as a 
deviation having an impact on the primary criterion. 
Examples of protocol deviations to be stated as major are following: 
â€¢ Patient not presenting, at the time of inclusion, with known or highly suspected focal areas of 
disrupted Blood Brain Barrier 
â€¢ Imaging protocol not respected with major impact on primary criterion 
â€¢ Informed consent not signed 
â€¢ IMP not injected  
 
Other major deviations can be specified during the course of the trial and the exhaustive list of major 
and non- major deviations will be provided in the statistical analysis plan.  
Major and non-major deviations will be presented apart by [CONTACT_555469]. 
11.3.4 Demographics and Baseline  Characteristics  
Demographic parameters are age, sex, race, ethnic origin, childbearing potential, body weight, height, 
and body mass index (BMI). Baseline characteristics are the patient 's history (including the medical 
history, the clinical indication for MRI and the presence or absence of brain metastasis) and the 
concomitant treatments.  
Summary statistics (number [n], mean, standard deviation [SD], median, minimum, and maximum) will be calculated for age, body weight, height and BMI. Frequency and percentages will be calculated 
for sex, patientâ€™s  history characteristics and concomitant treatments.  
Patient 's medical history will be coded using the MedDRA dictionary and tabulated by [CONTACT_6764], 
preferred term and status (concomitant or not).  
Patient 's concomitant treatments will be coded using the Anatomical Therapeutic Chemical (ATC)  
Drug dictionary and tabul ated by [CONTACT_157840].  
Demographics and baseline characteristics will be displayed by [CONTACT_555469].  
11.3.[ADDRESS_729171] agent group (gadopi [INVESTIGATOR_555337]) .  
The absolute (mL) and relative (%) differences between theoretical and actual volumes of trial product will be presented by [CONTACT_555471] . 
11.3.6 Efficacy Analysis   
Primary analysis  
Superiority of Paired images versus Pre images of gadopi[INVESTIGATOR_555411] -primary criteria  (for objective 1) 
For gadopi[INVESTIGATOR_555334], the difference â€œPairedâ€ - â€Preâ€ for e ach of 3 co-primary criteri a 1 will be analyzed 
using paired t -tests using the FAS 1. Results will be presented per reader.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 64 / [ADDRESS_729172] to meet the alternative hypothesis for the 3 co-primary 
criteria in the gadopi[INVESTIGATOR_555348]: a statistically significant (one -sided pâ‰¥0.025) positive difference in 
mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions. 
 
Non- inferiority of gadopi[INVESTIGATOR_555412]- primary 
criteria  (for objective 2) 
The Student â€™s t-based two-sided 95% confidence intervals of the difference between gadopi[INVESTIGATOR_555413] [ADDRESS_729173] 2 out of 3 readers 
and for the 3 co- primary criteria simultaneously , then non- inferiority between gadopi[INVESTIGATOR_555414].  
As soon as the non- inferiority is demonstrated, the superiority of the gadopi[INVESTIGATOR_555334] o ver gadobutrol will 
be tested using the same method  and using the  FAS2 and  PPS2. No adjustment for multiplicity is 
needed as it is a simple closed testing procedure.  
Secondary a nalyse s  
Additional analysis of the co -primary criteria   
Supportive analyses of the non-inferiority  analysis  
The non- inferiority  analysis will be repeated using the FAS2 .  
Assay sensitivity:   
For gadobutrol, the difference â€œPairedâ€ - â€Preâ€ for each of 3 co -primary criteria will be analyzed using 
the same analysi s as described for superiority on the FAS 2. Results will be presented per off- site 
reader.   
 
Intra -reader variability  
Intra -reader variability will be analyzed in a subgroup of 10% of patients randomly selected for whom 
the off -site readers have re- read the images.  
Intra -reader variability will be stu died by a Bland- Altman graph. Descriptive statistics and the Intra-
Class Correlation (ICC) will also be provided.  The analyses will be performed using the FAS1 and FAS2. 
 
Inter - reader variability  
Inter -reader variability will be evaluated on the whole set of trial patients , since each case was read by 
[ADDRESS_729174] agent groups,  except otherwise specified.  
 
Lesion visualization (on site) 
Same analysis as off -site lesion visualization criteria will be carried out for on -site evaluation  
 
Improvement in lesion visualization scores  at patient -level , paired versus pre images. 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 65 / [ADDRESS_729175] agent groups; off -site 
and on- site readerâ€™s outcomes will be separately analyzed . 
 
Technical adequacy of images  
Technical adequacy  and assessable status of images will be tabulated by [CONTACT_555472]; off- site and on -site readerâ€™s outcomes will be separately analyzed.  
Number of lesions  
The number of lesions per  patient  will be  tabulated by [CONTACT_555473]; MRI 
modalities (â€œPairedâ€ vs. â€œpreâ€) and contrast agent groups (gadopi[INVESTIGATOR_555415]. gadobutrol) will be 
compared with a multivariate model using the negative binomial distribution. O ff-site and on- site 
readerâ€™s outcomes will be separately analyzed.  
 
Size of lesions  
The size of the [ADDRESS_729176] agent groups; off -site and  on-
site readerâ€™s outcomes will be separately analyzed.  
 
Location of lesions  
The localization of the [ADDRESS_729177] representative lesions by [CONTACT_555474]-site readers 
and onâ€“site radiologists and will be displayed by [CONTACT_555475]; off-site 
and on- site readerâ€™s outcomes will be separately analyzed.  
 
Diagnostic confi dence 
The diagnosis of each lesion according to off -site readers and on -site radiologists will be displayed  by 
[CONTACT_555476]; off -site and on- site readerâ€™s outcomes will be separately 
analyzed.  
Diagnostic confidence will be tabulated by [CONTACT_555477]; off -site and  on- site readerâ€™s 
outcomes will be separately analyzed.  
 
Impact of contrast- enhanced MRI on patient treatment plan:  
The impact on patient treatment plan will be assessed by [INVESTIGATOR_2394] -site radiologists and will be tabulated by 
[CONTACT_555477] . 
 
Contrast to Noise Ratio (CNR)  
CNR  is calculated from the Signal Intensity (SI)  measurement of maximum 3 representative lesions by 
[CONTACT_941] 3 independent off- site readers (see section 7.2.8) 
For each reader, CNR will be tabulated by [CONTACT_555478] d ifferences between contrast 
agents will be tested using  a Studentâ€™s t -test.  
Percentage Enhancement (E% ) of lesion(s)  
E% is calculated from the Signal Intensity (SI) measurement of maximum 3 representative lesions by 
[CONTACT_941] 3 independent off -site readers (see section  7.2.8) 
For each reader, E% will be tabulated by [CONTACT_555478] d ifferences between contrast 
agents will be tested using  a Studentâ€™s t -test.  
Lesion to Background Ratio (LBR)  
LBR is calculated from the Signal Intensity (SI) measurement of maximum 3 representative lesions by 
[CONTACT_941] 3 independent off -site readers (see section  7.2.8)  
For each reader, LBR will be tabulated by [CONTACT_555479]  a Studentâ€™s t -test.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 66 / [ADDRESS_729178] media  preferred.  
11.3.7 Adverse E vent 
An overall summary of AEs will be presented using the Screened  Patient Set (SPS) to catch AEs of 
patients who did not receive trial drug. The table will be presented overall , only with the following 
variables:  
- Total number of AEs. 
- Total number of patie nts with at least one AE.  
- Distribution of the number of AEs reported by [CONTACT_1962]  (0, 1, 2 or 3 or more AEs). 
- Total number of Serious AEs (SAEs) according to the seriousness criteria. 
- Total number of patients  with at least one SAE  according to the ser iousness criteria. 
 - Total number of AESIs. - Total number of patients  with at least one AESI.  
- Total number of AEs according to intensity (severity) . 
- Total number of patients  with at least one AE according to intensity  (severity)   
- Total number of AEs according to the outcome. 
- Total number of patients  with at least one AE according to the outcome.  
- Total number of AEs requiring a concomitant drug (other action taken) /procedure. 
- Total number of patients  with at least one AE requiring a concomita nt drug/ therapeutic measures  
(other action taken) /procedure. 
- Total number of AEs leading to premature discontinuation. - Total number of patients with at least one AE leading to premature discontinuation. 
- Total number of AEs with causal relationship to the procedure. 
- Total number of patients with causal relationship to the procedure. 
 
The same overall summary will be displayed by [CONTACT_555480] 
(TEAEs) using the Safety Set. The following variables will be also presented:  
- Total number of TEAEs with causal relationship to the IMP. 
- Total number of patients  with at least one TEAE with causal relationship to the  IMP. 
- Total number of TEAEs requiring interruption  of IMP . 
- Total number of patients  with at least one TEAE requiring withdrawal of IMP . 
The number and percentage of patients  with at least one TEAE will be presented using the Safety Set 
by [CONTACT_555481]. 
The number and percentage of patients with at least one TEAE w ith causal relationship to the IMP 
will be presented using the Safety Set by [CONTACT_555481].  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 67 / [ADDRESS_729179] agent group. Pain at injection site will be measured using the Numeric Pain 
intensity Scale  (NPS) and NPS  measurements for these patient s will be tabulated by [CONTACT_555482]. 
 
Vital signs  
Vital signs will be analyzed quantitatively and qualitatively  by [CONTACT_555483] . Qualitative analyses 
will be done via  comparison of vital signs data to their normal ranges (see section 7.2.10) and 
according to their clinical ly significant changes. Quantitative analyses will be done by [CONTACT_555484].  
 
11.[ADDRESS_729180] on the primary and secondary criteria of 
analysis, no covariates are added in the efficacy models.  
 
11.4.2 Handling of Dropouts or Missing Data  
No imputation will be performed in this trial. 
 
11.4.3 Interim  Analyses  
No interim analysis is planned . 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 68 / 79 
 
 
 
11.4.4 Multicenter  Trial  
As a high number of sites  is expected for this trial, the site factor will not be included in the models for 
efficacy. The number of patients included in each site  will be displayed in a disposition table.  
11.4.5 Multiple Comparisons /Multiplicity  
For FDA, the primary objective 1 is to be achieved. The primary objective 2 will serve as one of the 
secondary objectives.  
For EMA, both primary objectives 1 and 2 are to be achieved   
Therefore, no multiplicity adjustment is needed for this trial as only one objective should be reached 
for FDA and the two primary objectives should be reached simultaneously for EMA.  
Furthermore, each objective (superiority of Paired vs Pre, and non- inferiority of the two contrast 
agents), will be considered achieved only if the null hypothesis is rejected for the [ADDRESS_729181] two readers out of three. Each reader will be analyzed separately.  
 
11.4.6 Use of an "Efficacy Subset" of patients  
As the primary objective 1 is superiority, the corresponding analysis will be done using the Full 
Analysis Set and then the analysis repeated using the Per Protocol Set.  
As the primary objective 2 is non- inferiority, the corresponding analysis will be done using the Per 
Protocol Set and then the analysis will be repeated using the Full Analysis Set.  
11.4.7 Examination of Subgroups  
No examination of subgroups is planned.  
 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 69 / 79 
 
 
12 TRIAL  COMMITTEES  
Based on safety related to non- specific macrocyclic GBCAs and results of gadopi[INVESTIGATOR_555416] I to IIb 
trial, no committee will be set up for this trial.  
The overall gadopi[INVESTIGATOR_555417] (based on consolidated  available data from all gadopi[INVESTIGATOR_555418])  will be evaluated and follow ed up by [CONTACT_555485], therefore no 
specific trial committee will be set up . 
The Guerbet Safety Committee whom core members are the European Qualifi ed Person responsible 
for Pharmacovigilance (EU -QPPV), the Development, Medical and Regulatory Affairs Director, the 
Global Head of Regulatory Affairs who is also the Head of Preclinical Development including 
additional members such as medical expert [INVESTIGATOR_555499][INVESTIGATOR_555419] (e.g. Initial Signal Report) every [ADDRESS_729182] on other documents (e.g. clinical studies 
documents, etc.). The appropriate actions are  taken accordingly. 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 70 / 79 
 
 
13 ETHICAL AND REGULATORY CONSIDERATIONS  
13.1 References  
The trial/  will be conducted in accordance with the following regulatory / guidance texts: 
- World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research 
Involving Human Subjects, June 1964, and amended in: October 1975 (Tokyo), October 1983 
(Venice), September 1989 (Hong Kong), October 1996 (Somerset West), Scotland, October 
2000 (Edinburgh), 2002 (Washington), 2004 (Tokyo), October 2008 (Seoul) , October 2013 
(Fortaleza)  
- International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use: Integrated Addendum to I CH E6(R1): Guideline for Good 
Clinical Practice E6 (R 2) Current Step 4 version dated 19  November 2016 
- International Conference on Harmonisation (ICH) of Technical Requirements for Registration 
of Pharmaceuticals for Human Use: Clinical Safety Data Management: Definitions and 
Standards for Expedited Reporting E2A Current Step 4 version dated 27 October 1994 
- International Conference on Harmonisatio n (ICH) of Technical Requirements for Registration 
of Pharmaceuticals for Human Use: General Considerations for Clinical Trials E8
 Current 
Step 4 version dated 17 July 1997  
- Directive 2001/20/EC of the European Parliament and of the Council of [ADDRESS_729183] of clinical trials on 
medicinal products for human use 
- Commission Directive 2003/94/EC of [ADDRESS_729184] of medicinal products for human use and investigational medicinal products for human use 
- Commission Directive 2005/28/EC of 8 April 2005 laying down princ iples and detailed 
guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such 
products 
- International Conference on Harmonisati on (ICH) of Technical Requirements for Registration 
of Pharmaceuticals for Human Use: Ethnic Factors in the Acceptability of Foreign Clinical Data E5(R1)
 Current Step 4 version dated 5 February 1998  
- Regulation (EU ) 2016/[ADDRESS_729185] to the processing of personal data and on the 
free movement of such data, and repealing Directive 95/46/EC (General Data Protection 
Regulation) 
- EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice - Medicinal Products for Human and Veterinary 
Use, Annex 13 Investigational Medicinal Products  
- US Food and Drug Administration, Title 21 Code of Federal Regulat ions Part 11 on 
Electronic Records ; Elec tronic Si gnatures 
- US Food and Drug Administration, Title 21 Code of Federal Regulations Part 211 on Current Good Manufacturing Practice for Finished Pharmaceuticals  
- Regional / local regulations and other specific populations regulations
 
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 71 / [ADDRESS_729186]/Independent Ethics Committee and 
Regulatory/Competent Authorities  
As per international regulation, the clinical trial may be initiated only after having received the 
approval by [INVESTIGATOR_54146]/Independent Ethics Committee (IRB/IEC) and the 
authorization by [CONTACT_555486]/Competent Authority. The final written approval and 
authorization must be available for a given investigational site when initiating the trial conduct at this 
particul ar site. Amongst all documents required locally, the approval and authorization must be 
obtained for the protocol, investigatorâ€™s brochure, the patient informed consent form and any other 
written information or document to be provided to the patients.  
In case of modifications to the trial  protocol, patient  informed consent form or any other written 
information provided to the patient s, or to any trial procedure; the modified documents will be 
submitted to IRB/IEC and Regulatory/Competent Authority opi[INVESTIGATOR_6153].  Modifications may be 
implemented when the final approval and authorization are available.  
In case of an emergency situation when the patient sâ€™ safety may be at risk, Guerbet may implement 
emergency safety measures prior to obtaining IRB/IEC approval and Regulatory/Competent Authority 
opi[INVESTIGATOR_1649]. In parallel to implementing these measures, Guerbet will immediately notify the concerned 
IRB/IEC and Regulatory/Competent Authorities of such implementation. 
The documentation related to the approvals and authorizat ions must be filed in the T rial Master File at 
Guerbet and at the investigational sites in their respective Investigational Site File (ISF).  
Notification of Serious Adverse Events/Reactions to IRB/IEC and Regulatory/Competent Authority 
will be made according to the national requirements. Safety reporting is described in Section  9 of the 
present protocol.  
Notifications of non- compliance / deviations to IRB/IEC and Regulatory/Competent Authority will be 
made according to national requirements of participating countries and according to indiv idual 
IRB/IEC requirements when applicable. 
 
13.[ADDRESS_729187] confirm their free and voluntary willingness to participate in 
the trial. This confirmation is obtained in writing after having received a full oral and written 
explanation on the trial: 
- Aims, methodology and duration of the trial; 
- Potential benefits, foreseeable risks and inconveniencies related to the trial; 
- Rights and responsibilities of patients, with particular emphasis on the right to refuse trial 
participation or to withdraw consent to participation at any time without consequences or 
penalties;  
- Information on IMP and its administration; 
- Contact [CONTACT_555487].  
The language used when inf orming the patients and answering their questions must be as 
understandable as possible and shall not induce any misunderstanding or feeling to be influenced to 
participate. Patients must be given ample time to decide whether they agree to participate or n ot. 
Patient s may consent to participate after having received all necessary information and all satisfactory 
answers to their questions. Their consent must be confirmed in writing by [CONTACT_555488](s) approved by [CONTACT_555489]/IEC.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 72 / 79 
 
 
When the consent may not be directly obtained in writing, a legal representative/impartial witness may 
be involved in the process and confirm in writing that the patient  consented freely and voluntarily.   
Such involvement(s) must be fully documented in the patientâ€™s medical records and the informed consent.  
The information of patient s may only be conducted by [CONTACT_555490], whose 
involvement and responsibility for patient  information has been fully documented and approved by [CONTACT_1268].  
The Principal Investigator [INVESTIGATOR_555420]/requirements are fully observed by [CONTACT_555491]/his responsibility. 
In case of modifications of the patient  informed consent or of any othe r document to be provided to 
the patient s, the IRB/IEC approval must be obtained prior to implementing the new document(s). 
Patient s who already consented may be asked to confirm their willingness to continue participating in 
writing. In any case, the same information and consent process as described above must be followed. 
 
13.4 Trial  Records  and Archiving  
The investigator/institution should maintain adequate and accurate source documents and trial records 
that include all pertinent observations on each of the siteâ€™s trial patient s. Source data should be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry, and should be explained if necessary (e.g., 
via an audit trail).  
The investigator is responsible for supervising any individual or party to whom the inve stigator 
delegates trial -related duties and functions conducted at the trial site. 
During the course of the clinical trial, investigational sites must ensure completeness and accuracy of the trial records that are to be filed in the Investigator Site File  (ISF) provided by [CONTACT_555492]. The completeness and accuracy of such files will be checked regularly by [CONTACT_555493] (Clinical Research Associate (CRA) or Monitor). The final check will occur at the close 
out visit when inves tigational site participation is over.  
At the end of the trial, investigational sites must ensure the ISF will be archived in an appropriate way that allows timely access and proper retention of documents. Retention period will be of at least 15 years afte r trial completion. Sites should obtained Guerbet written approval before destroying trial 
documents.  
 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 73 / 79 
 
 
14 QUALITY CONTROL  / QUALITY ASSURANCE  
14.[ADDRESS_729188] Access to Source Data/Documents  
The investigator will allow Guerbet representatives, the persons responsible for the audit, the 
representatives of the Ethics Committees and of the Regulatory Authorities to have direct access to 
source data/documents. 
The investigator must guarantee the safety of the trial  data in the medical files by [CONTACT_555494].  
The investigator undertakes, in accordance with the regulation in force, to make anonymous any 
patient  data before collection by [CONTACT_555429]. Especially the name [CONTACT_555504] s will be 
deleted from any medium such as clinical  eCRF, document for biological results, X -Ray films or 
digital supports.  
- For this trial, the following will be considered as source data: patient sâ€™ medical files, images.  
- If computerized medical files are used, the system must be evaluated by [CONTACT_555429] (or 
representative):  In case printing of files is not possible, the computerized system must be 
validated and access should be granted to Guerbet or its representative. 
If the computerized system is not validated, the in vestigator must, at the start of the trial, print, sign 
and date all the medical files of all patient s and during the trial , print, sign and date in real time each 
data entry and each data change. 
 
14.2 Clinical Monitoring  
Before the trial is conducted at a giv en investigational site and until the trial  is completed/terminated at 
the same given investigational site, Guerbet will mandate a representative to perform a close 
monitoring of the trial conduct that will ensure that the investigational site is properly equipped; the 
staff is adequately experienced and knowledgeable of regulatory and ethical requirements.  Monitors 
contact [CONTACT_555495].  
The representative will perform regular investigational site visits and report all discu ssions, patient  and 
IMP data verification performed with particular attention to patient sâ€™ safety and well -being and trial 
data accuracy and completeness.  All monitoring procedures and requirements will be described in a 
monitoring plan. 
 
14.3 Clinical Data Han dling  
14.3.1 Data Reported in the e CRF  
The clinical eCRF  will allow recording of data required by [CONTACT_760], except detailed central 
laboratory results  and blinded imaging assessment performed by [CONTACT_555496]. 
The investigator or the designated person from his/her team agrees to complete the eCRF, at each 
patient  visit, and all other documents provided by [CONTACT_555429] (e.g. documents relating to the IMP 
managementâ€¦) and to reply to any data clarifications raised in a timely manner.  
The investigator must attest:  
- The authenticity of the data collected in the clinical  eCRF;  
- The consistence between the data in the clinical  eCRF and those in the source documents. 
No data entered in clinical eCRF may be considered as source data.  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 74 / 79 
 
 
14.3.2 Data Reported in the clinical eCRF according to patient Status  
A minimal set of screen failure information is required to ensure transparent reporting of screen failure 
patient  to respond to potential queries from regulatory  authorities.  
Minimal information includes demography, screen failure details (listed on â€˜end of trial clinical  eCRF 
page), eligibility criteria, and any serious adverse event (SAE). Additional information such as 
medical history, concomitant medication etcâ€¦might be requested in case of SAE.  
For patient s discontinued from the trial after randomization, all data available at the time of 
discontinuation will be reported in the medical file and the clinical eCRF (e.g.: inclusion data, safety 
data, administration data, imaging data, reason for premature discontinuationâ€¦). The investigator 
must make every effort to collect and record all follow -up safety information (i.e., adverse events, 
injection -site tolerance, as appropriate), unless the patient  withdraws c onsent for further data 
collection/participation for/in the trial . 
 
14.3.3 Data Management S ystem  
A validated clinical data management system will be used for data process and data storage.  
Data processing and control will be closely managed by [CONTACT_555429]â€™s represen tative.  
 
14.[ADDRESS_729189], Competent/Regulatory Authorities may also carry out 
an inspection in the facilities of Guerbet and/or the investigational sites. Guerbet will inform all the investigators immediately upon notification of a pending inspection. Likewise, the investigator will 
inform Guerbet of any pending inspection. 
Whether for an audit or for a regulatory inspection, Guerbet and the investigational sites both agree to 
cooperate in full transparency, confidentiality and professional secrecy.  
The investigator must allow the representatives of Guerbet (audit) and/or of the Competent/Regulatory Authorities (inspection):  
- To inspect the site, facilities and trial material,  
- To meet all members of his/her team involved in the trial,  
- To have direct access to trial data and source documents,  
- To consult all of the documents relevant to the trial.  
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 75 / 79 
 
 

 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 76 / 79 
 
 
16 REFERENCES  
 
1. Colosimo  C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi -
center, intra -patient comparison of gadobenate dimeglumine -enhanced MRI with routinely 
used contrast agents at equal dose. Invest Radiol 2001;36:72â€“ 81 
2. Knopp  MV, Runge V M, Essig M, et al. Primary and secondary brain tumors at MR imaging: 
bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate 
dimeglumine. Radiology 2004;230:55â€“ [ADDRESS_729190]-enhanced MRI of intracranial tumours. Neuroradiology 2004;46:655â€“ 65 
4. Essig  M, Tartaro A, Tartaglione T, et al. Enhancing lesions of the brain: intraindividual 
crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 2006;13:744â€“[ADDRESS_729191] enhancement of central nervous 
system lesions: multicenter intraindividual crossover comparative study of two MR contrast 
agents. Radiology 2006;240:389â€“400 
6. Kuhn  MJ, Pi[INVESTIGATOR_477295] P, Maldjian JA, et al. Evaluation of  intraaxial enhancing brain tumors on 
magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and 
implications for surgical intervention. J Neurosurg 2007;106:557â€“ [ADDRESS_729192] -enhanced MR imaging of brain lesions: a 
large -scale intraindividual crossover comparison of gadobenate dimeglumine versus 
gadodiamide. AJNR Am J Neuroradiol 2008;29:1684â€“91 
8. Rumboldt  Z, Rowley HA, Steinberg F, et al. Multicenter, double -blind, randomized,intra -
individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine 
in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760â€“[ADDRESS_729193] 
Studies in the evaluation of Brain Metastases. AJNR Am J Neuroradio 1994; 15:1053-[ADDRESS_729194] -
enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double- blind, Randomized, Comparator Study. Magnetic Resonance Insights 
2015;8:1â€“10 
11. EMA. Guideline on the choice of the non-inferiority margin. 
https://www.ema.europa.eu/documents/scientific- guideline/guideline -choice-non- inferio rity-
margin_en.pdf 
 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 77 / 79 
 
 
17 COMPANY LIABILITY INSURANCE  
Guerbetâ€™s liability, as well as the liability of the investigators participating to this trial, is covered by 
[CONTACT_555497], a copy of the certificate being submitted to the investigator.  
Furthermore,  Guerbet and the investigator undertake to comply with the locally applicable legal 
requirements with respect to insurance.  
However, Guerbet and its insurer reject all liability in the following cases, which are merely indicative and not exhaustive: 
â€¢ An accident due to a cause other than the investigational medicinal product administered,  
â€¢ An accident occurring during use of the investigational medicinal product differently from the 
instructi ons given in the trial  protocol , 
â€¢ An accident occurring for a patient whose consent to participation was not adequately 
collected . 
  
 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 78 / [ADDRESS_729195] the number corresponding to the pain intensity. 
  

 
 
CONFIDENTIAL  Protocol No. GDX -44-010 
Version No. V1.0 
December 20,  2018 Page 79 / 79 
 
 
18.2 Volume of IMP  injection by [CONTACT_555498][INVESTIGATOR_555334] (0.5M)  gadobutrol (1M)  
 
Adults  Dose (mmol/kg)  Dose (mmol/kg)  
0.05 0.1 
Dose (ml/kg)  Dose (ml/kg)  
0.1 0.1 
Body Weight  Volume  (mL)  Volume  (mL)  
Kilograms (kg)  Pounds (lb)  
40 88 4 4 
50 110 5 5 
60 132 6 6 
70 154 7 7 
80 176 8 8 
90 198 9 9 
100 220 10 10 
110 242 11 11 
120 264 12 12 
130 268 13 13 
140 308 14 14 
150 330 15 15 
 